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ABSTRACT 
 
BUDDY A. WHITMAN: Neuroimmune consequences of chronic alcohol exposure: 
relationship to stress.  
  (Under the Direction of Dr. George R. Breese) 
 
 
Alcoholism is characterized by tolerance to alcohol, withdrawal signs or symptoms, 
and continued use despite detrimental physical or psychological consequences.  Studies have 
illustrated the deleterious effects of prolonged and excessive alcohol use extend to many 
organs including the liver, lungs, stomach, and brain.  While the brain represents the most 
important organ in the development and maintenance of alcoholism, the neurobiological 
mechanisms underlying its role are not sufficiently understood to permit effective and timely 
intervention.  Recent work has demonstrated that alcohol-associated changes in 
neuroimmune function may contribute to the progression of alcoholism.  To better 
understand the role of alcohol in neuroimmune system dysregulation, changes in cytokine 
expression were determined after alcohol exposure in rats.  While acute alcohol 
administration did not increase proinflammatory cytokines measured in the cerebral cortex, 
chronic alcohol administration produced a robust effect.  Additionally, HMGB1, an 
endogenous activator of the neuroimmune system, was elevated following chronic alcohol 
administration.  Stress, a major contributor to relapse in abstinent alcoholics, activates the 
neuroimmune system and, like alcohol, has been shown to increase cytokines in brain.  The 
effects of stress and chronic alcohol on brain cytokines were examined in combination.  A 
stress challenge following chronic alcohol exposure caused a more pronounced increase in
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brain cytokines.  Because HMBG1 was elevated following chronic alcohol exposure, the 
possibility that stress was contributing to the release of HMGB1 was examined.  Blockade of 
HMBG1 with two different antagonists reduced stress-induced increases in cytokines 
following chronic alcohol exposure.  This work illustrates that 1) chronic alcohol exposure 
increases neuroimmune activity and 2) stress following chronic alcohol exposure causes a 
greater activation of the neuroimmune system.  Blockade of HMGB1 blocked the stress-
induced production of cytokines following chronic ethanol exposure.  Therefore, this work 
highlights a critical pathway of activation associated with chronic alcohol use and provides a 
valuable target system for future therapies.   
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CHAPTER I: 
 GENERAL INTRODUCTION 
 
Current diagnostic criteria define alcohol dependence by the presence of at least three 
of the following criteria for more than a year: tolerance, alcohol withdrawal signs or 
symptoms, drinking more than intended, unsuccessful attempts to reduce drinking, excessive 
time spent related to alcohol, impaired social or work activities due to alcohol and continued 
use despite physical or psychological consequences (DSM IV, 1994).  Alcohol abuse is 
defined by the presence of a minimum of one of the following criteria for more than a year: 
role impairment, hazardous use, legal problems, or social or interpersonal problems due to 
alcohol (DSM IV, 1994).  The lifetime prevalence of alcohol dependence is 12.5%; that of 
alcohol abuse is 17.8% (Hasin et al., 2007).  According to the latest report from the World 
Health Organization, alcohol is responsible for 4.5% of the total disease burden worldwide 
(WHO, 2009).  These statistics underscore the importance of research into the mechanisms 
underlying alcoholism. 
Although alcohol abuse affects many organs throughout the body, its effects on the 
brain may represent the most significant component in maintaining this abuse.  A number of 
factors have been implicated in initiating and sustaining alcohol abuse and alcoholism.  In 
addition to neuronal factors, dysregulation of the neuroimmune system has recently come to 
light as playing a significant role in an adaptive process induced by chronic ethanol exposure 
(Crews et al., submitted; He and Crews, 2008; Pascual et al., 2011; Qin et al., 2008).  Further, 
chronic ethanol exposure has been found to enhance the effects of stress (Breese et al., 2004; 
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reviewed in Breese et al., 2011), which may also involve the neuroimmune system (Breese et 
al., 2008; Knapp et al., 2011).  
The Neuroimmune System 
The innate immune response in brain consists of a rapid response to stimuli from 
microglia and infiltrating macrophages (Glezer et al., 2007).  Microglia respond to various 
signals via specific pattern-recognizing receptors (PRR) including the pathogen-associated 
molecular pattern (PAMP) receptors such as the toll-like receptor (TLR).  A key part of the 
innate immune response, TLRs are responsible for recognizing and responding to pathogens.  
Activation of toll-like receptor 4 (TLR4) induces a complex signaling cascade resulting in 
the recruitment of one of  two major adaptor molecules myeloid differentiation factor-88 
(MyD88) or TIR-domain-containing adaptor-inducing interferon-β (TRIF) (reviewed in 
Vartanian and Stenzel-Poore, 2010).  Differential activation of each pathway is condition 
dependent and results in a wide array of potential responses (Vartanian and Stenzel-Poore, 
2010).  For example, recruitment of MyD88 can culminate in transcription of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB), activation of which induces a 
proinflammatory response.  Recruitment of TRIF can culminate in transcription of interferon 
regulatory factor (IRF), activation of which induces late-phase NF-κB activation and co-
stimulatory molecules (Akira and Takeda, 2004).   
Besides responding to exogenously introduced pathogens, TLRs recognize 
endogenous damage-induced alarmins or damage-associated molecular patterns (DAMPS) 
(Garg et al., 2010).  It has recently been suggested that one of these alarmins, high-mobility 
group protein B1 (HMGB1), in conjunction with changes in the endogenous receptors for 
HMGB1, may contribute to the dysregulation of the neuroimmune system by ethanol (Crews 
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et al., submitted; Pascual et al., 2011).  Such changes are accompanied by the prolonged 
increase in cytokines observed following chronic ethanol exposure in mice (Qin et al., 2008) 
and human alcoholics (He and Crews, 2008).  
TLR4 and Alcohol 
Recent experimental studies demonstrate a link between alcohol and activation of the 
neuroimmune system via TLR4 signaling (Alfonso-Loeches et al., 2010; Blanco et al., 2005; 
Fernandez-Lizarbe et al., 2008; 2009; Wu et al., 2012).  It has been proposed that ethanol’s 
action at TLR4 receptors is similar to that of lipopolysaccharide (LPS) agonist action on this 
receptor (Fernandez-Lizarbe et al., 2008).  Specifically, Fernendez-Lizarbe et al. (2008) 
provide evidence that low to moderate concentrations of ethanol facilitate the recruitment of 
TLR4 receptors into lipid rafts in a manner similar to that of LPS stimulation (Triantafilou et 
al., 2002).  The authors suggest that this mechanism is responsible for the increase in brain 
cytokines associated with TLR4 signaling.   
Results of studies of acute ethanol effects on LPS-induced cytokines have been 
inconsistent.  It has been reported that acute ethanol inhibits LPS-induced, TLR4-mediated 
proinflammatory responses in vivo and in vitro (Crews et al., 2006; Dai et al., 2005; Pruett 
and Fan, 2009).  For example, Pruett and Fan (2009) found acute ethanol inhibition of LPS-
induced cytokines in serum and peritoneal fluid 24 hr following a 6 g/kg (i.g.) dose of 
ethanol as well as after doses as low as 3 g/kg (i.g.) (Pruett and Pruett, 2006).  On the other 
hand, Qin et al. (2008) found that, 24 hr after a single intragastric (i.g.) dose of ethanol (5 
g/kg ), the LPS-induced chemokine (C-C motif) ligand 2 (CCL2) and tumor necrosis factor-
alpha (TNFα) were not inhibited by acute ethanol in brain, serum, or liver and that the 
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interleukin-1 beta (IL1-β) response was potentiated.  Considered in aggregate, these 
observations suggest multiple modes of neuroimmune action for acute ethanol.   
In contrast to acute ethanol, chronic ethanol exposure is characterized by elevated 
levels of proinflammatory cytokines in the liver (Qin et al., 2008; Valles et al., 2003), brain 
(Qin et al., 2008), and serum (McClain and Cohen, 1989; McClain et al., 1999; Qin et al., 
2008).  Additionally, prior chronic ethanol exposure potentiates the effects of LPS challenge 
on cytokines (Crews et al., 2006; Qin et al., 2008).   
Knockout mouse models of TLR4 exhibit protection from various consequences of 
chronic ethanol exposure in accord with a relationship to TLR4 function.  For example, 
Uesugi et al. (2001) found TLR4-deficient mice to be protected against ethanol-induced liver 
injury.  The protective nature of TLR4 knockout extends further to prevention of the 
inflammatory response induced by ethanol in glia (Alfonso-Loeches et al., 2010; Fernandez-
Lizabre et al., 2009) and protection from neurodegeneration induced by chronic ethanol 
intake (Alfonso-Loeches et al., 2010).  Further, Pascual et al. (2011) found that the persistent 
memory deficits and anxiety-related behavioral impairment seen in wild-type mice following 
chronic ethanol exposure were not observed in TLR4 knockout mice.  Wu et al. (2012) found 
that inhibition of the TLR signaling pathway either by knockout or pharmacological means 
reduced the sedation and motor impairment associated with ethanol.  Taken together, these 
studies show a critical role of TLR4 signaling in the pathology associated with chronic 
ethanol exposure.   
HMGB1  
Originally identified as a nonhistone deoxyribonucleic acid (DNA) binding protein 
responsible for nucleosome stabilization and facilitation of transcription (Ellwood et al., 
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2000; Goodwin et al., 1973), high-mobility group protein B1 (HMGB1) has a second, 
extracellular role in the mediation of inflammation (Kim et al., 2006; Park et al., 2004; Yang 
et al., 2005).  Extracellular HMGB1 has been implicated in the pathology of many diseases 
including liver and lung inflammation (Abraham et al., 2000), sepsis (Wang et al., 1999), 
arthritis (Lotze and Tracey 2005), cancer (Lotze and Tracey 2005), epilepsy (Maroso, et al., 
2010), and multiple sclerosis (Andersson et al., 2008).  HMGB1, a nuclear associated 
protein, is released from cells either passively (e.g., necrotic cells; Scaffidi et al., 2002) or 
actively [e.g., activated macrophages and monocytes (Wang et al., 1999) and neurons and 
astrocytes (Faraco et al., 2007)].  Active secretion of HMGB1 involves several steps: (1) 
HMGB1 exclusion from the nucleus due to hyper-acetylation (Palumbo et al., 2004); (2) 
sequestration into cytoplasmic secretary lysosomes; and (3) exocytosis (Gardella et al., 2002; 
Yang et al., 2011).  Once released, extracellular HMGB1 can bind directly to TLR2/4 and to 
the receptor for advanced glycation end product (RAGE) to instigate inflammatory responses 
(Green et al., 2009; Park et al., 2006; Rovere-Querini et al., 2004; Yu et al., 2006).  HMGB1 
is a key regulator of the innate immune response and works in a feed-forward mechanism to 
activate RAGE, TLR2, and TLR4 (Yang et al., 2010).  Activation of RAGE by HMGB1 
leads to activation of ERK and p38 pathways to activate transcription factor NF-κB (Rauvala 
and Rouhiainen, 2007).  Activation of TLR2 or TLR4 by HMGB1 also leads to the activation 
of NF-κB through the MyD88 pathway (Park et al, 2004).  Evidence also suggests that 
HMGB1 functions as a universal sentinel for nucleic acid-mediated innate immune responses 
(e.g., nucleic-acid-sensing TLRs 3,7,9) (Yanai et al., 2009) and may also enhance 
proinflammatory responses by binding to cytokines and potentiating their actions (Sha et al., 
2008).  
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Stress and the Neuroimmune System 
Stress differs from traditional pathogenic or traumatic mediators of neuroimmune 
activation in that it is a “sterile” stimulus.  Little is known about this recently recognized role 
of stress as a “sterile” activator of the neuroimmune system (Andersson and Tracey, 2011).  
However, several studies have demonstrated that various acute stress protocols increase brain 
cytokines (Blandino et al., 2009; Deak et al., 2005).  Knapp et al. (2011) documented that the 
protein levels of TNFα were elevated in whole brain 4.5 hr following a 1-hr restraint stress in 
adult rats.  Similar results were obtained in adolescent rats.  TNFα protein levels were 
elevated 5 hr- after 45-min or 90-min restraint stress in adolescent rats (Knapp, unpublished 
data).  Not all stressors activate a central proinflammatory response (Deak et al., 2003; Plata-
Salaman et al., 2000), however.  The effects of stress on neuroimmune function might differ 
as a function of factors such as duration, intensity, and type of stressor (Hueston et al., 2011).  
Sugama et al. (2009) showed that acute stress was associated with concomitant activation of 
microglia and neurons.  This association of microglial activation with neuronal activation 
may explain the rapid activation of the neuroimmune system following stress.   
Neuroimmune Sensitization 
  Results of several studies suggest that alterations in basal levels of regulatory 
elements of the neuroimmune system may underlie the increased sensitivity to subsequent 
neuroimmune system challenge.  Barnum et al. (2008) were the first to report that individual 
differences in basal levels of cytokine expression in the brain predicted neuroimmune 
consequences to an acute stress challenge.  Girotti et al. (2011) demonstrated that 
neuroimmune reactivity can be sensitized by a chronic stress paradigm leading to increased 
reactivity to a subsequent stress challenge.  Ling et al. (2006) reported priming of microglia 
by immunological stimulation during critical periods.  Godbout et al. (2005) reported priming 
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of microglia resulting in exaggerated inflammatory responses to additional stimuli in aging.  
While neuroimmune sensitization has thus been consistently observed, the mechanisms of 
neuroimmune sensitization have not been elucidated to date.   
Research Objective  
  Several lines of evidence suggest that neuroimmune activation and, ultimately, 
sensitization to such activation could be persistent consequences of continuous ethanol 
exposure.  Ethanol has been shown to increase cytokines in vivo and in vitro in animal 
models.  Zou and Crews (2010) showed induction of proinflammatory cytokines TNFα, 
MCP-1, and IL-1β in brain slice cultures exposed to ethanol.  Ten days of ethanol exposure 
(5g/kg/day) significantly increased both messenger ribonucleic acid (mRNA) expression and 
protein levels of TNFα and interleukin-6 (IL-6) in mice (Crews et al., submitted).  Human 
alcoholics have abnormalities in basal cytokine tone (He and Crews, 2008) and other 
neuroimmune regulatory elements (Liu et al., 2006; Okvist et al., 2007).  Furthermore, when 
presented with aversive imagery, abstinent alcoholics show enhanced neural activation 
compared to nondrinkers measured by functional magnetic resonance imaging (fMRI) 
(Gilman and Hommer, 2008), a finding consistent with the presence of central sensitization 
to neural activation.  Breese et al., (2004) demonstrated a reemergence of anxiety-like 
behavior induced by a single acute restraint stress in rats 3 days following cessation of 
chronic ethanol treatment.   
Data presented by Crews et al. (submitted) suggest that HMGB1, in concert with 
TLRs, underlies ethanol-associated neuroimmune activation and the sensitization of the 
neuroimmune response following chronic ethanol exposure.  However, the potential roles 
HMGB1 and cytokine tone play in stress activation of the neuroimmune system following 
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chronic ethanol exposure is not currently understood.  The purpose of this research was to 
explore the means by which ethanol and stress alone and in combination influence 
neuroimmune mechanisms in the brain.  
  
 
CHAPTER II:  
GENERAL METHODS 
Animals  
Adult male Sprague Dawley rats (Charles-River, Raleigh, NC) were obtained at 180-
200g.  Upon arrival, animals were group housed and fed RMH3000 rat chow (TestDiets, 
Richmond, IN) for 2-3 days prior to the start of the study to acclimate to the new 
environment (temperatures 70-72˚ F; humidity 40-60% ; and light/dark cycle 12hr:12hr, 
lights on 7:00-19:00hrs).  All animals were singly housed for the duration of the experiments 
herein.  All study methods were approved by the University of North Carolina Chapel Hill 
Institutional Animal Care and Use Committee.  
Liquid Diet  
A nutritionally complete and calorically balanced liquid diet was made from a 
lactalbumin-dextrose-based mixture with added vitamins and minerals (Dyets, Bethlehem, 
PA) and used for the control diet (CD) or ethanol diet (ED) protocols as previously described 
and used routinely in the lab (e.g., Frye et al., 1983; Knapp et al., 1998; 2007a; 2011; 
Overstreet et al., 2002; Wills et al., 2008).  CD was calorically balanced to the ED with 
adjustments of the amount of dextrose in each diet.  Rats were fed either CD or 7% ethanol 
(wt/vol) in a modified pair-feeding system as noted under protocols for experiments in this 
paper (Fig. 2.1 and 2.2).  Volumes consumed each day were measured following the end of 
the dark cycle (09:00 hr).  To minimize weight differences throughout the experiments, the 
volume of CD the control rats received each day was adjusted to the amount of ED the 
ethanol exposure group drank on the previous day.  Additionally, weights were monitored 
weekly throughout the experiments.  Unless otherwise noted, all animals were 24 hr into 
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withdrawal when sacrificed, well beyond when blood alcohol levels (BALs) would have 
returned to zero (Overstreet et al., 2002).   
Acute Ethanol Protocol  
A single dose of ethanol was administered via oral gavage.  The 2.75 g/kg oral dose 
was chosen (Fig. 2.1A) to approximate peak levels (≈185-200 mg% BAL) previously found 
with chronic ethanol diet protocols (Overstreet et al., 2002; Wills et al., 2008).  Four hr 
following ethanol or saline administration, the rats were sacrificed and brains collected as 
described below.   
Acute LPS Protocol  
To determine the effects of a single exposure to LPS (Calbiochem, La Jolla, CA), rats 
were injected intraperitoneally (i.p.) (250μg/kg  at 125 μg LPS/ml) and sacrificed 4 hr later 
(n=16, Fig. 2.1B).  Brains were collected and tissue processed as described below.   
Continuous Ethanol Protocol  
To determine the effects of continuous ethanol exposure, rats were provided with 
liquid diet (7% wt/vol) for 15 continuous days (Frye et al., 1983) and sacrificed 24 hr into 
withdrawal (n=32, Fig. 2.1C).  Brains were collected and processed for biochemistry as 
described below.   
Chronic LPS Protocol  
The effects of chronic LPS administration on brain cytokines were determined after 
10 consecutive daily i.p. injections of LPS (250 μg/kg) (n=32, Fig. 2.1D).  Animals were 
sacrificed and brains harvested 24 hr following final injection.  
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Time Course Following Continuous Ethanol Protocol  
To determine the time of peak brain cytokine production and the duration of changes, 
animals were sacrificed 24, 48, and 72 hr and 7 days following withdrawal from the 
continuous ethanol protocol (n=40, Fig. 2.1E).  Brains were collected and processed as 
described below.   
Multiple Withdrawal Protocol   
To compare the effects of continuous ethanol exposure with those of cycled ethanol 
exposure, rats were exposed to three 5-day bouts of ED separated by 2 days of CD 
(Overstreet et al., 2002) (n=28, Fig. 2.1F).  The rats were sacrificed 24 hr into the third 
withdrawal period and the brains collected for cytokine measurement. 
Continuous Ethanol with Stress Challenge Protocol  
To determine the effects of stress following continuous ethanol exposure, rats were 
provided with ED (7% wt/vol) for 15 continuous days (Frye et al., 1983) and withdrawn for 
24 hr prior to a 1-hr restraint stress.  Four hr following the restraint stress, the animals were 
sacrificed and brains were immediately collected and frozen for later processing for 
biochemistry as described below (n=64, Fig. 2.2A).  
Acute Stress Time Course Protocol  
To determine the time course of changes in cytokines following acute stress 
application, rats were subjected to 1 hr of restraint stress and brains were collected 2, 4, 8, 24, 
and 48 hr later (n=40, Fig. 2.2B). 
Continuous Ethanol with HMGB1 Antagonism Prior to Stress Challenge Protocol  
To determine if the effects of stress following continuous ethanol exposure could be 
prevented by blockade of HMBG1 signaling, rats were provided with liquid diet for 15 
continuous days and withdrawn for 24 hr.  Fifteen minutes prior to a 1-hr restraint stress, rats 
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were treated with either glycyrrhizin or ethyl pyruvate.  Four hr following the restraint stress, 
the animals were sacrificed and brains were collected and processed for biochemistry as 
described below (n=40, Fig. 2.2C).  
 Drug Preparations 
 LPS was prepared in a solution of sterile saline at 125 μg/ml and administered at 2 
ml/kg to equal a dose of 250 μg/kg i.p.  Glycyrrhizin was prepared in a solution of sterile 
saline at 25 mg/ml and administered at 2 ml/kg to equal a dose of 50 mg/kg i.p. (Ohnishi et 
al., 2011).  Ethyl pyruvate was prepared in a solution of sterile saline at 37.5 mg/ml and 
administered at 2 ml/kg to equal a dose of 75 mg/kg i.p. (Su et al., 2011).  All control 
subjects received i.p. injections of sterile saline at 2 ml/kg.   
Brain Tissue Collection  
All brains were collected following rapid decapitation.  Whole brains were extracted 
and immediately frozen in isopentane at -25˚ C prior to storage at -80˚ C for later 
microdissection of the cortex.  Cortical tissue was divided into two halves to provide tissue 
for quantitative real-time polymerase chain reaction (qPCR) analysis.   
Real-Time RT-PCR Analysis 
 Total RNA was extracted from homogenized microdissected cortex regions using Trizol 
(Invitrogen, Carlsbad, CA) and used for reverse transcription PCR analysis as described elsewhere (Qin 
et al., 2008). The following primer sequences were used:  CCL2, 5'- 
TCACGCTTCTGGGCCTGTTG-3' (forward) and 5'- CAGCCGACTCATTGGGATCATC-3' 
(reverse); IL1-β, 5'- GAAACAGCAATGGTCGGGAC-3' (forward) and 5'- 
AAGACACGGGTTCCATGGTG-3' (reverse); TNFα, 5’- ATGTGGAACTGGCAGAGGAG -3’ 
(forward) and 5’- ACGAGCAGGAATGAGAAGAGG-3’ (reverse); TLR4, 5’- 
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GCCGGAAAGTTATTGTGGTGGT-3’ (forward) and 5’-ATGGGTTTTAGGCGCAGAGTTT-3’ 
(reverse); NF-κB, 5'- GGCAGCACTCCTTATCAA -3' (forward) and 5'- 
GGTGTCGTCCCATCGTAG -3' (reverse);  MyD88, 5'- GGCAGGCTGCTAGAGTTGCT -3' 
(forward) and 5'- TGTGGGACACTGCTCTCCAC-3' (reverse); HMGB1, 5'- 
GAGATCCTAAGAAGCCGAGA-3' (forward) and 5'- CTTCCTCATCCTCTTCATCC-3' (reverse);  
β-actin, 5'- ATGGTGGGTATGGGTCAGAAGG -3' (forward) and 5'- 
GCTCATTGTAGAAAGTGTGGTGCC-3' (reverse).  SYBR green PCR master mix (Applied 
Biosystems, Foster City, CA) was used for  qPCR analysis.  The cycle time (CT) values were 
normalized with β-actin to assess the relative differences in expression between groups.  Calculated 
values were expressed as relative change compared to controls set as 100%.   
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CHAPTER III:   
INCREASED CYTOKINE PRODUCTION IN BRAIN FOLLOWING CONTINUOUS 
ETHANOL EXPOSURE IS ASSOCIATED WITH ELEVATION OF HMGB1 
 
Introduction 
Although alcohol abuse affects many organs throughout the body, its effects on brain 
contribute most significantly to the pathology of abuse.  Among several factors implicated in 
initiating and sustaining alcohol abuse and alcoholism, dysregulation of the neuroimmune 
system has recently come to light as playing a significant role in adaptive processes induced 
by continuous ethanol (Alfonso-Loeches et al., 2010; Breese et al., 2008; Crews et al., 
submitted; He and Crews 2008; Knapp et al., 2011; Pascual et al., 2011; Qin et al., 2008).  
Recent experimental studies have demonstrated a link between ethanol and the activation the 
neuroimmune system via TLR4 signaling (Alfonso-Loeches et al., 2010; Blanco et al., 2005; 
Fernandez-Lizarbe et al., 2008; Fernandez-Lizarbe et al., 2009; Wu et al., 2012).  However, 
in vivo evidence of TLR4 signaling effects of acute and chronic ethanol compared with those 
of LPS, the prototypical TLR4 ligand, is conflicting (Okun et al., 2009).  
It has been proposed that ethanol’s action at TLR4 receptors is similar to that of 
(LPS) agonist action on this receptor (Fernandez-Lizarbe et al., 2008).  Specifically, 
Fernendez-Lizarbe et al. (2008) provide evidence that low to moderate concentrations
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of ethanol facilitate the recruitment of TLR4 receptors into lipid rafts in a manner similar to 
that of LPS stimulation (Triantafilou et al., 2002).  Crews et al. (submitted) found increased 
expression of TLR4 in post-mortem human alcoholic frontal cortex as well as in mice 
following extended continuous ethanol administration.  Further, knockout mouse models of 
TLR4 have shown protection from various consequences of continuous ethanol exposure in 
accord with an involvement of TLR4 in ethanol action.  For example, Uesugi et al. (2001) 
found that TLR4- deficient mice were protected from ethanol-induced liver injury.  This 
protective effect of knocking out TLR4 extends to prevention of the inflammatory response 
induced by ethanol in glia (Alfonso-Loeches et al., 2010; Fernandez-Lizabre et al., 2009) and 
the neurodegeneration induced by chronic ethanol intake (Alfonso-Loeches et al., 2010).  
Pascual et al. (2011) found that the persistent memory deficits and anxiety-related behavioral 
impairment seen in wild-type mice following chronic ethanol exposure were not observed in 
TLR4 knockout mice.  Taken together, these studies implicate TLR4 signaling in the 
pathology associated with chronic ethanol exposure.  Further, Wu et al. (2012) found that 
inhibition of the TLR signaling pathway either by knockout or pharmacological means 
reduced the sedation and motor impairment associated with acute ethanol administration.  
Collectively, these studies provide convincing evidence that TLR4 receptors contribute to 
ethanol action on brain.   
Ethanol is unlikely to be a direct agonist for TLR4 signaling.  To shed light on the 
mechanism of ethanol-initiated, TLR4-mediated changes in cytokines, the present 
investigation compared the effect of LPS with that of acute and chronic ethanol on brain 
mRNAs for cytokines and measures of TLR4 signaling.   
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Materials and Methods 
 
Animals  
For standard animal housing and diet procedures, refer to General Methods (Chapter 
II). 
Experimental Protocols 
 For detailed descriptions of experimental protocols, refer to General Methods 
(Chapter II).  Briefly, acute ethanol exposure consisted of a dose of 2.75 g/kg administered 
via oral gavage (i.g.) of a 20% wt/vol ethanol and distilled water solution.  Control animals 
for the acute ethanol study received an i.g. volume of water equivalent to the average volume 
of the ethanol-treated animals.  Both control animals and ethanol-treated animals were 
sacrificed 4 hr following ethanol or water administration and brains collected immediately.  
For the acute LPS protocol, 250 μg/kg was administered via i.p. injection of 125 μg LPS/ml 
in sterile water. Control animals for the acute LPS protocol received an i.p. injection of 
sterile saline equivalent to the average volume of the LPS administered to the LPS treated 
animals in the study.  Both control animals and LPS-treated animals were sacrificed 4 hr 
following LPS or water administration and brains collected immediately.   
The continuous ethanol protocol consisted of ED or CD for 15 consecutive days.  ED 
was provided ad libitum to half the animals in the study.  CD was adjusted daily to balance 
calorically the amount the ED animals consumed the previous day.  This modified pair-
feeding design balances weight gain between control and experimental animals.  All animals 
in this experiment were sacrificed 24 hr into withdrawal for brain collection.  Animals in the 
chronic LPS experiment received i.p. injections of 250 μg/kg for 10 consecutive days.  
Control animals received i.p. injections of sterile water equivalent to the average volume 
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given to the LPS-treated animals.  All animals in this experiment were sacrificed 24 hr 
following final LPS injection for brain collection.  The protocol for the time course following 
continuous ethanol exposure is as described above with additional animals sacrificed at 24, 
48, and 72 hr and 7 days following removal of ethanol after day 15.  All animals were 
maintained on rat chow following the initial 24-hr withdrawal.  Control animals were 
sacrificed at each time point to account for any differences in age of animals.  Animals in the 
multiple withdrawal experiment received ED for 3 cycles of 5 consecutive days with 2 days 
of CD between each cycle of ED and were sacrificed 24 hr after withdrawal from the third 
cycle of ED.   
Statistical Analysis  
All data were evaluated for statistical significance with student’s t-test or analysis of 
variance (ANOVA) as appropriate using Graph Pad Prism 4.0 (Graph Pad Software, Inc., 
San Diego, CA) and expressed as mean ± standard error of the mean (SEM).  P-values < 0.05 
were considered statistically significant.   
Results 
Comparison of Acute Ethanol to Acute LPS  
To evaluate the effects of acute ethanol (Fig. 2.1A) versus acute LPS (Fig. 2.1B) on 
brain cytokine mRNAs, rats were exposed to an acute dose of either ethanol or LPS.  Four hr 
after administration of the single dose of ethanol (2.75 g/kg), no significant increases in 
CCL2, IL1-β, or TNFα mRNA (p>0.05; Fig. 3.1A) were observed.  When an additional 
group of rats (n=12) was assessed 24 hr following this acute ethanol exposure (2.75 g/kg), no 
significant increases in CCL2, IL1-β, or TNFα mRNA were observed at this extended period 
(all p>0.05, Fig.3.1, legend).  Unlike acute ethanol, which did not affect cytokine mRNA 
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levels, an acute dose of LPS (250 μg/kg) caused a several-fold increase in CCL2 (432%), 
IL1-β (337%), and TNFα (920%) mRNAs (all p<0.0001 Fig. 3.2B).  Neither an acute dose of 
ethanol nor an acute dose of LPS increased TLR4 mRNA at 4 hr (all p>0.05; Fig. 3.1C & 
3.1D).  Thus, while acute ethanol exposure did not affect cytokine mRNAs at 4 or 24 hr after 
the exposure, acute LPS caused a several-fold increase in mRNAs for CCL2, IL1-β, and 
TNFα at 4 hr.  Neither exposure affected TLR4 mRNA.  The effects of acute ethanol on 
cytokine mRNAs, thus, clearly differ from those of acute LPS. 
Comparison of Continuous Ethanol to Chronic LPS  
To assess potential differences in the effect of continuous ethanol and chronic LPS 
exposure on cytokines in brain, mRNAs for CCL2, IL1-β, and TNFα were measured 24 hr 
following 15 consecutive days of ethanol exposure (7% ethanol wt/vol in liquid diet) or 
following 10 daily doses (250 μg/kg) of LPS.  The mRNAs for all cytokines showed 
significant increases over controls (CCL2, 144.9%; IL1-β 97.3%; TNFα 125.0%; all p<0.05, 
Fig. 3.2A) 24 hr following the continuous ethanol protocol.  In contrast, 24 hr after the 
chronic LPS protocol, no significant increases were observed for any of these cytokine 
mRNAs (all p>0.05; Fig. 3.2B).  A significant increase in TLR4 mRNA was found 24 hr 
after both the continuous ethanol protocol (63.3% increase) and the chronic LPS (79.2% 
increase) protocol (all p<0.05, Fig. 3C & 3D, respectively).  The effects of continuous 
ethanol on cytokine mRNAs, thus, clearly differ from those of chronic LPS.  
Time Course of Changes in Cytokines Following Continuous Ethanol   
In previous studies in mice, increased brain neuroimmune gene expression induced by 
5 months of ethanol liquid diet was dependent upon TLR4 receptors (Alfonso-Loaches et al., 
2010).  In other mouse studies, chronic ethanol exposure increased neuroimmune gene 
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expression 24 hr after the last exposure (Pascual et al., 2007; Qin, et al., 2008).  In rats, 16 hr 
of abstinence from chronic ethanol exposure was associated with induction of a peak 
expression of cyclooxygenase 2 (COX2), a proinflammatory oxidase (Knapp and Crews, 
1999).   
 Based upon these previous findings, mRNA expression for CCL2, IL1-β, and TNFα 
was measured in brain at various times (0 and 24 hr and 3 and 7 days) after 15 days of 
continuous ED (Fig. 2.1C).  No change in cytokines was observed in the rats sacrificed while 
still exposed to ethanol, (i.e., T=0; no abstinence; Fig. 3.3).  However, after 24 hr of 
abstinence, expression of CCL2 increased by 102%, IL1-β by 93.8%, and TNFα by 107% 
(all p<0.05)—findings in agreement with results in Fig. 3.2.  Following the increase after 24 
hr of ethanol abstinence, cytokine mRNAs gradually declined toward control levels by 3 days 
(72 hrs.); CCL2= 67.7%, IL1-β=100.9%, and TNFα=60.7% increase over contols (Fig. 3.3).  
The mRNA levels for all cytokines had returned to control levels by 7 days (Fig. 3.3).  These 
findings confirm that continuous ethanol exposure followed by abstinence for 24 hr increases 
mRNA expression of CCL2, IL1-β, and TNFα in brain. Values peak at 24 hr, and changes do 
not persist beyond 7 days. 
Comparison of Continuous and Cycled Ethanol   
Cycled ethanol exposure increase withdrawal symptoms such as susceptibility to 
seizures and anxiety-like behavior more than a comparable continuous alcohol exposure does 
(McCown and Breese, 1990; Overstreet et al., 2002).  This observation prompted studies to 
determine if differences in proinflammatory gene induction are observed after these different 
modes of chronic ethanol exposure (Breese et al., 2005, 2011).  It was found that CCL2, IL1-
β, and TNFα brain mRNA significantly increased with both continuous ethanol exposure 
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(CCL2, 79.8% increase; IL1-β, 102.3% increase; TNFα, 96.2%) and cycled ethanol exposure 
(CCL2, 70.5% increase; IL1-β, 82.0% increase; TNFα, 108.4%) 24 hr after ethanol 
withdrawal (all p<0.05 vs. control; Fig. 3.4A).  However, no difference between the 
continuous ethanol group and the cycled ethanol was observed (p>0.05; continuous vs. 
cycled ethanol).  Like the cytokine mRNAs, TLR4 mRNA was increased by both the 
continuous ethanol exposure (122.6%) and the intermittent cycled ethanol exposure (85.2%) 
(p<0.05), but the increases did not differ between groups (p>0.05; Fig. 3.4B).  Data from this 
study replicate results from the continuous ethanol investigation (Fig. 3.2), in which CCL2, 
IL1-β, TNFα, and TLR4 mRNAs were initially found to be increased 24 hr after ethanol 
withdrawal.  Continuous ED and cycled ED increased expression of brain CCL2, IL1-β, 
TNFα and TLR4 mRNA to similar degrees after 24 hr of abstinence from ethanol.  
Effects of Continuous and Cycled Ethanol on HMGB1, My88, and NFκB   
In addition to determining mRNAs for cytokines for both continuous and cycled 
ethanol (Fig. 3.4A), mRNA changes in TLR4 (Fig. 3.4B) and the mRNAs for HMBG1, 
MyD88 and NFκB (Fig. 3.4C) were determined in these groups.  The mRNA for TLR4 was 
increased by both ethanol protocols (Fig. 3.4B) as was the mRNA for HMGB1 (continuous 
ethanol, 64.4%; cycled ethanol, 57.3%; p<0.05; Fig. 3.4C).  However, the difference between 
the continuous ethanol group and the cycled ethanol group in changes in mRNA for HMGB1 
was not statistically significant (p>0.05).  Further, neither continuous nor cycled ethanol 
caused a significant change in levels of MyD88 or NF-κB mRNA (p>0.05; Fig. 3.4C).  Thus, 
both the continuous and cycled ethanol protocols increased expression of the mRNA for 
HMGB1, an agonist for TLR4, as well as the mRNA for the TLR4 in brain. 
HMGB1 Response After Continuous Ethanol vs. Chronic LPS   
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Whether the increase in HMGB1 by the continuous ethanol protocol would also be 
observed after chronic LPS exposure was investigated in a study comparing HMBG1 
response after continuous ethanol versus chronic LPS.  Consistent with results shown in Fig. 
3.4C, the continuous ethanol exposure significantly elevated HMGB1 mRNA by 102.8% 
(Fig. 3.5A) (p<0.05) without inducing a significant change in either MyD88 or NF-κB 
(p>0.05) (Fig. 3.5A).  Unlike continuous ethanol, chronic LPS did not increase HMGB1, 
MyD88, or NF-κB (all p>0.05) (Fig. 3.5B).   
 The time course of the HMGB1 change was determined from the tissue utilized in the 
experiment described in Fig. 3.4.  At the time prior to ethanol removal (T=0), the level of 
HMGB1 was elevated by 65% (Fig. 3.6).  By 24 hr, the HMGB1 was significantly elevated 
to 119% of control (p<0.05) in agreement with the increase noted in Fig. 3.5B.  
Subsequently, HMGB1 mRNA levels decreased to control levels by 72 hr and were 88% 
below control levels by 7 days after ethanol removal (p<0.05; Fig. 3.6).  While TLR4 
expression was not elevated at T=0 in the rats that received continuous ethanol exposure 
(Fig.3.6), the TLR4 level was elevated by 68.3% 24 hr after withdrawal from ethanol 
(p<0.05, Fig.3.6) in corroboration of data in Fig. 3.2C.  TLR4 mRNA returned to control 
levels by 72 hr and was 81% below control levels by 7 days (p<0.05; Fig. 3.6).   
Discussion 
 
LPS increases cytokines by acting as an agonist at TLR4s (Erridge et al., 2002; Okun 
et al., 2009). Several studies support a role of TLR4 signaling in ethanol-induced increases in 
cytokine production.  For example, in TLR4 knockout mice, ethanol activation of effects 
mediated by TLR4 signaling are absent in astrocytes (Blanco et al., 2005; Valles et al., 2004), 
cultured microglia (Fernandez-Lizarbe et al., 2008; Fernandez-Lizarbe et al., 2009), and 
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brain (Alfonso-Loeches et al., 2010).  TLR4 knockout mice also show altered acute ethanol 
responses (Wu et al., 2012).  Fernendez-Lizarbe et al. (2008) suggested that ethanol induces 
cytokines in brain by causing accumulation of TLR4s and related signaling molecules into 
lipid rafts to induce signaling through TLR4s.  This hypothesis is compelling but incomplete.  
The mechanism by which continuous ethanol involves TLR4 function to increase cytokines 
in brain remains unclear, particularly because ethanol cannot act as an agonist on TLR4s.  
The present studies were undertaken to explore possible mechanisms by which chronic 
alcohol might influence TLR4 signaling to increase cytokines in brain.  Effects on 
proinflammatory gene expression and signaling proteins of LPS, the prototype TLR4 direct 
agonist, were compared with those of acute and continuous ethanol. 
 The results show that an intoxicating acute dose of ethanol did not increase mRNA 
for CCL2, TNFα, IL1-β, or TLR4 in cortex of Sprague-Dawley rats 4 or 24 hr after 
administration.  Consistent with these findings, Buck et al. (2011) found no increase in 
mRNAs for IL-6 or IL1-β in Sprague-Dawley rats 12 hr after 4 g/kg of ethanol.  However, 
Qin et al. (2008) found increased mRNAs for TNFα and CCL2, but not IL1β, 24 hr after a 
single 5 g/kg oral dose of ethanol.  The discrepant results of Qin et al. (2008) might be 
explained by the use of mice rather than rats and/or by use of a higher dose of ethanol in the 
mouse studies than in the rat studies. 
 Unlike acute ethanol, which did not cause acute cytokine changes, acute 
administration of LPS (250 µg/kg) caused a several-fold increase in mRNAs for CCL2, 
TNFα, and IL1-β by 4 hr. LPS did not increase mRNA for TLR4.  The increase in brain 
cytokines by acute LPS is consistent with published reports (Qin et al., 2007; 2008; Chen et 
al., 2005).  Qin et al. (2007) suggested that the LPS induction is based upon entrance of 
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blood-borne TNFα into the brain, where it contributes to the cytokine increase by LPS.  
Whether this mechanism of TNFα entrance from the periphery to brain is critically 
responsible for the LPS-induced changes observed in the present study could be determined 
by administering LPS into brain.  Regardless, the present findings provide clear evidence for 
a fundamental difference between the effects of acute LPS on brain cytokine changes and 
those of acute ethanol at the doses studied.   
 Unlike acute ethanol, which did not cause acute cytokine changes, continuous ethanol 
exposure (continuous 7% alcohol diet for 15 days) approximately doubled CCL2, IL1-β, and 
TNFα in the cortex of rats 24 hr after ethanol removal (Fig. 3).  TLR4 levels were also 
increased after this continuous ethanol protocol. Previous studies in C57Bl/6 mice found that 
chronic administration of ethanol (5 g/kg, i.g.) for 10 days followed by 24 hr of ethanol 
abstinence increased brain CCL2 and TNFα but not IL1-β or other cytokine mRNAs (Qin et 
al., 2008).  
 Unlike continuous ethanol, chronic LPS (250 µg/kg daily for 10 days) produced no 
change in CCL2, IL1β, and TNFα mRNA in the cortex of the rats 24 hr after the final LPS 
dose.  Like continuous ethanol, however, chronic LPS induced a significant increase in 
TLR4.  Thus, continuous ethanol differed from chronic LPS in effects on mRNA changes in 
cytokines although both increased TLR4 mRNA in brain.   
 A complete time course for cytokine mRNAs induced by continuous ethanol revealed 
that mRNAs for TLR4 and cytokines were not different from control when the ED had not 
been removed (i.e., at T=0).  In agreement with initial findings, mRNAs for cytokines were 
significantly increased by 24 hr after the ethanol removal.  However, the mRNA levels for 
these cytokines gradually declined over 3 days (i.e., by 72 hr) and returned to control levels 
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by 7 days after cessation of continuous ethanol exposure.  These findings indicate that 
chronic 7% ED increases CCL2, IL1β, TNFα, and TLR4 mRNA in brain with peak effects 
approximately 24 hr after abstinence from ethanol.  
 Previous studies in this lab established that multiple intermittent cycles of ethanol 
exposure are more effective than continuous ethanol exposure at engendering symptoms of 
ethanol withdrawal (Overstreet et al., 2002; Breese et al., 2011) or supporting an increased 
sensitivity to kindling of seizures (McCown and Breese, 1990).  Based on the possibility that 
multiple withdrawals from alcohol might have a greater effect on the induction of brain 
cytokines than continuous alcohol exposure, these two modes of chronic alcohol exposure 
were compared for their ability to induce cytokine mRNAs 24 hr following withdrawal from 
ethanol.  As found earlier, continuous liquid diet exposure increased cortical CCL2, IL1β, 
and TNFα mRNAs.  The chronic intermittent exposure to ethanol (cycled ethanol) also 
elevated CCL2, IL1β, and TNFα in cortex—changes almost identical to those observed with 
the continuous alcohol exposure. Further, both continuous and intermittent ethanol treatments 
increased the mRNA for the TLR4.  Thus, effects of chronic intermittent ethanol exposure 
were comparable to those of continuous ethanol exposure—a finding inconsistent with the 
hypothesized “kindling process continuum” responsible for facilitation of withdrawal anxiety 
or facilitation of kindling of seizures (Breese et al., 2005a; 2011).  Possibly, kindling-like 
effects on mRNAs were not observed because the cortex, the brain site examined in the 
current investigation, does not mediate the kindling-like effects observed after chronic 
ethanol exposure in previous studies (i.e., increased susceptibility to seizures [McCown and 
Breese, 1990], facilitation of anxiety [Breese et al., 2011]).  This possibility warrants 
exploration in future investigations. 
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 In the current investigation, mRNA for the endogenous agonist for TLR4s, HMGB1 
(Andersson and Tracey, 2011; Lin et al., 2011), was elevated by both continuous and cycled 
ethanol protocols without significant changes in mRNAs for MyD88 (Janssens and Beyaert, 
2002) or NF-κB (Baeuerle and Henkel, 1994; Fitzgerald et al., 2003)—signaling proteins 
linked to TLR4 function (Fig.3.5C).  Based upon the finding that HMGB1 mRNA was nearly 
doubled 24 hr after the two modes of chronic alcohol exposure, an investigation was initiated 
to assess HMGB1 mRNA changes over time during and after the continuous chronic alcohol 
protocol.  HMGB1 mRNA was moderately elevated prior to cessation of the chronic alcohol 
diet (T=0)—a time when TLR4 and cytokine mRNAs were not different from control 
(Fig.3.6).  By 24 hr after cessation of chronic alcohol, the mRNA for HMGB1 was 
significantly elevated (Fig.3.6) as were the mRNAs for cytokines (Fig. 3.3). HMGB1 and 
TLR4 mRNAs gradually fell to control levels by 3 days and were below control levels by 7 
days after ethanol removal (Fig. 3.6).  The time course, prior to and after the continuous 
ethanol exposure, of the change in HMGB1 mRNA was similar to the time courses of the 
changes in the cytokine mRNAs.  These changes occurred in the absence of effects on 
MyD88 or NF-κB 24 hr after cessation of continuous ethanol exposure (Fig. 3.5C).  This 
continuous-ethanol-induced increase in HMGB1 and TLR4s possibly explain the ethanol 
induction of brain TNF, CCL2, and IL1-β.  
 Although both continuous ethanol and chronic LPS increased TLR4 mRNA in brain, 
chronic LPS, unlike continuous ethanol, did not significantly change CCL2, IL1β, or TNFα 
mRNAs in the cortex of the rats 24 hr after the final dose.  Considered in aggregate, the 
results suggest the possibility that HMGB1 may be the endogenous ligand that activates the 
TLR4 to increase brain cytokines after abstinence from the continuous ethanol protocol.  The 
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intriguing possibility that HMGB1 released onto TLR4s during withdrawal from chronic 
alcohol may be responsible for the increase in brain cytokines would help to explain earlier 
findings relevant to TLR4s and ethanol action (Alfonso-Loeches et al., 2010; Blanco et al., 
2005; Fernandez-Lizarbe et al., 2008; 2009; Valles et al., 2004).   
 The capacity for HMGB1 to induce cytokines is documented in the literature (Faraco 
et al., 2007; Lin et al., 2012; Andersson and Tracy, 2011; Mϋller et al., 2001; Yang et al., 
2005).  In a recent study, Crews et al. (submitted) observed that HMGB1 neutralizing 
antibodies added to brain slice cultures blunted the ability of ethanol to induce IL1-β, a 
finding consistent with the possibility that ethanol activation of IL1-β occurs through 
HMGB1/TLR signaling.  Similarly, the in vivo increase in brain TNF, CCL2, and IL1-β after 
withdrawal from the continuous ethanol protocol in the current investigation could be linked 
to ethanol release of HMGB1 onto TLR4s.  The present studies provide a foundation for 
future work to further elucidate the mechanisms of ethanol-associated increases in brain 
cytokines during excessive exposure to ethanol, ethanol withdrawal or neural injury. 
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Figure 3.1: Effects of acute ethanol versus acute LPS administration on mRNA for cytokines 
CCL2, IL1-β, TNFα and for TLR4s in cortex.  Cytokine induction was observed following 
acute LPS (250 mg/kg) but not acute ethanol (2.75 g/kg). A) An acute single dose of ethanol 
resulted in no significant increase in mRNA of cytokines CCL2, IL1-β, or TNFα (all p>0.05) 
at 4 hr post administration.  B) An acute single dose of LPS at 250 mg/kg increased mRNA 
of cytokines CCL2, IL1-β, and TNFα (CCL2 t(17)=6.07,  p<0.0001; IL1-β t(16)=6.31,  
p<0.0001; TNFα t(13)=4.97,  p=0.0003) 4 hr following injection. C) Acute ethanol did not 
alter TLR4 mRNA expression (p>0.05). D) Acute LPS did not alter TLR4 expression 
(p>0.05).   
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Figure 3.2: Effects of continuous ethanol versus chronic LPS administration on mRNA for 
cytokines CCL2, IL1-β, TNFα and for TLR4s in cortex.  Cytokine induction differed 
between animals treated with a continuous ethanol protocol and those treated with a chronic 
LPS protocol.  A) Cytokines CCL2, IL1-β, and TNFα were increased 24 hr into withdrawal 
following continuous ethanol exposure compared to non-treated controls (t(15)=4.53, 
p=0.0004; t(20)=3.42,  p=0.0027; t(21)=5.443,  p<0.0001, respectively). B) No significant 
increase in cytokine mRNA was observed 24 hr after chronic LPS exposure (all p<0.05).  C) 
Continuous ethanol exposure significantly increased TLR4 mRNA expression (t(23)=2.669,  
p=0.0137).  D) Chronic exposure to LPS significantly increased TLR4 mRNA expression 
(t(18)=2.83,  p=0.0112).   
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Figure 3.3: Time course of cytokine mRNA following continuous ethanol administration.  
Peak expression of CCL2, IL1-β, and TNFα was observed 24 hr after withdrawal.  A) CCL2 
peaked at 24 hr (F(4,25)= 3.06, p=0.035, Control 100 ± 31.1  vs. 24 hrs. 202.0 ± 33.3, 
p=0.025).  IL1-β peaked at 24 hr (F(4,27)= 5.05, p=0.036, Control 100 ± 11.0  vs. 24 hrs. 
193.8 ± 38.9, p=0.0039).  TNFα also peaked at 24 hr (F(4,27)=7.30 , p=0.0004, Control 100 
± 9.3  vs. 24 hrs. 207.3 ± 38.7, p=0.0006).   
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Figure 3.4: Effects of continuous and cycled ethanol exposure on mRNA for cytokines, 
TLR4 and the signaling molecules HMGB1, MyD88 and NF-κB in cortex.  A) No difference 
in cytokine mRNA was found between continuous ethanol and cycled ethanol exposure.  
CCL2, IL1-β, and TNFα from both the continuous and cycled ethanol treated groups showed 
significant increases (F(2,18)= 5.211, p=0.018; F(2,24)=9.718, p=0.0009; F(2,25)=6.475, 
p=0.006, respectively).  No significant differences were observed between the continuous 
and cycled ethanol treated groups (p>0.05).  B) TLR4 mRNA was elevated in both the 
continuous and cycled ethanol groups (F(2,23)=8.744, p=0.0017), but no differences were 
observed between the continuous and cycled ethanol exposure groups (p>0.05).  C) Both 
continuous and cycled ethanol exposure caused an elevation in HMBG1 mRNA 
(F(2,24)=3.787, p=0.0466); no differences were observed between continuous and cycled 
ethanol groups (p>0.05).  Neither continuous nor cycled ethanol affected levels of MyD88 or 
NF-κB (p>0.05).   
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Figure 3.5:  Effects of continuous ethanol versus chronic LPS administration on mRNA for 
HMGB1, MyD88 and NF-κB.  A) HMGB1, but not MyD88 or NF-κB, mRNA was elevated 
following continuous ethanol exposure over nontreated controls (HMGB1; t(16)=3.618,  
p=0.0023; MyD88, ns; NF-κB, ns). B) Chronic LPS did not cause an increase in HMGB, 
MyD88 or NF-κB mRNA levels (all p<0.05). 
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Figure 3.6:  Time course of changes to mRNA for HMGB1 and TLR4 following continuous 
ethanol. TLR4 was also significantly increased following continuous ethanol exposure and 
peaked at 24 hr (F(4,27)=8.64, p=0.0001, Control 100 ± 13.9  vs. 24 hr 168.3 ± 15.1, 
p=0.012).  HMGB1 was also significantly elevated (F(2,26)=3.51, p=0.02).  HMGB1was 
significantly elevated at T=0 (Control 100 ± 21.9, vs. 0 hr 164.5 ± 15.6) and peaked at 24 hr 
(Control 100 ± 21.9, vs. 218.7 ± 19.4).  
 
 
 
 
 
 
 
 
 
 
  
 
CHAPTER IV:  
ACUTE STRESS FACILITATION OF BRAIN CYTOKINES AFTER CONTINOUS 
ETHANOL EXPOSURE IS PREVENTED BY HMGB1 ANTAGONISTS 
Introduction 
 Stress has been shown to play a role in craving and risk of relapse (Breese et al., 
2005b; 2010; Sinha et al., 2000; Miller et al., 2009; Sinha et al., 2011).  In abstinent 
alcoholics, stress increases activation in brain as measured by fMRI—a change not seen in 
social drinkers (Gilman and Homer, 2008, reviewed in Breese et al., 2011).  In accord with 
fMRI studies, stress was a more salient initiator of craving than a drug cue (Breese et al., 
2011).  In rats, Breese et al. (2005c) found that the anxiety-like response to restraint stress 
was elevated after chronic ethanol exposure.  Additionally, Breese et al. (2005a) found that 
restraint stress could substitute for the first two withdrawal episodes in a chronic intermittent 
ethanol protocol to facilitate withdrawal-induced anxiety-like behavior (Breese et al., 2005a).  
Later studies in the lab showed that LPS or specific cytokines could substitute for stress or 
the first two withdrawal episodes in a chronic intermittent ethanol protocol (Breese et al., 
2008).  
Chronic exposure to high doses of ethanol can elevate cytokines (Alfonso-Loeches et 
al., 2010; Blanco et al., 2005; Crews et al., submitted; Fernandez-Lizarbe et al., 2008).  In 
human post-mortem brain tissue, He and Crews (2008) reported elevated levels of CCL2; and 
Crews et al. (submitted) showed elevated levels of cytokine mRNA and protein following 
chronic ethanol exposure in mice.  Additionally, results from Chapter III demonstrate
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increased mRNAs for cytokines CCL2, IL1-β, and TNFα in brain 24 hr following withdrawal 
from 15 days of continuous ethanol exposure.   
Stress is a powerful activator of the neuroimmune system (Blandino et al., 2009; 
Deak et al., 2005; Girotti et al., 2011; Hueston et al., 2011; Minami et al., 1991; Nguyen et 
al., 1998, 2000; Shizuya et al., 1997; Suzuki et al., 1997; Knapp et al., 2011).  Several studies 
have demonstrated that proinflammatory cytokines IL-1β and IL-6 are elevated in brain 
following various acute stress paradigms (Blandino et al., 2009; Deak et al., 2005; Minami et 
al., 1991; Nguyen et al., 1998; Shizuya et al., 1997; Suzuki et al., 1997), but see Hueston et 
al. (2011) for comparison of various acute stress paradigms.  Knapp et al. (2011) showed that 
protein levels of TNFα were significantly elevated in whole brain 4.5 hr following a 60-min 
restraint stress.  TNFα levels were also significantly elevated in whole brains collected from 
adolescent rats 5 hr following 45 or 90 min of restraint stress (Knapp, unpublished data).  
Activation of the neuroimmune system activates NF-κB transcription, which increases the 
expression of genes including proinflammatory cytokines and DAMP receptors such as 
TLR4 (Garg et al., 2010; Okun et al., 2009).  Although the mechanism for activation of the 
neuroimmune system by acute stress remains unclear, several reports suggest that activation 
of microglia (Miller et al., 2009; Wang and Dow, 2003; Wang et al., 2002) is responsible for 
the increase in proinflammatory cytokines.  These data suggest that the increase in cytokines 
observed following acute stress may be an important sterile (non-infection-based) 
neuroimmune challenge (Andersson and Tracey, 2011).  
To test changes in sensitivity of the neuroimmune response to stress following 
chronic ethanol, the present investigation initially established the duration of changes in brain 
cytokines following a 1-hr restraint stress.  Next, whether stress-induced increases in brain
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 cytokines would be enhanced following continuous ethanol exposure was determined.  
Finally, whether the activity of HMGB1 reported in Chapter III following continuous ethanol 
exposure contributes to stress activation of cytokines was tested pharmacologically by 
blocking HMBG1 just prior to a stress challenge.  One antagonist, glycyrrhizin, is a direct 
inhibitor of HMGB1 and binds HMGB1 in the extracellular space (Girard, 2007; Mollica et 
al., 2007).  This antagonist has been shown to be effective in vivo at blocking HMGB1 
function in rats (Ohnishi et al., 2011).  The second HMGB1 antagonist, ethyl pyruvate, has 
been shown to block the release of HMGB1 without any decrease in expression of mRNA or 
protein (Ulloa et al., 2002).  Given the upregulation of HMGB1 following continuous ethanol 
(Chapter III), it was hypothesized that HMGB1 may play a critical role in increased 
sensitivity of the neuroimmune system following continuous ethanol exposure. 
Materials and Methods 
Animals  
For standard animal housing and diet procedures, refer to General Methods (Chapter 
II). 
Experimental Protocols 
 For detailed descriptions of experimental protocols, refer to General Methods 
(Chapter II).  Briefly, to test for increased sensitivity of the neuroimmune system following 
continuous ethanol exposure a 1-hr restraint stress was applied 24 hr following removal of 
ethanol. Animals were sacrificed and brains harvested as described in Chapter II (Fig. 2.2).  
This experiment included (1) a group of rats (Controls) that only received CD for the entire 
procedure and did not receive a stress; (2) a group of rats that received CD for the duration of 
the experiment and a stress at the end; (3) a group that only received ED for the entire 
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duration; and (4) a group that received both ED for the entire duration plus a 1-hr restraint 
stress 24 hr into withdrawal.   
 To test for the duration of changes in cytokines, TLR4, and HMGB1 following 1 hr 
of restraint stress, rats were subjected to a 1-h. restraint stress and sacrificed at 2, 4, 8, 24, 
and 48 hr, and brains harvested as described in Chapter II.  Control rats (i.e., non-stressed) 
were included at all time points to control for differences in time of day and disturbance in 
animal care facility.   
 To assess the role of HMGB1 in the increased sensitivity of the neuroimmune system 
following continuous ethanol exposure, two known blocking agents of HMGB1 were applied 
15 min prior to application of stress.  This experiment contained six groups: (1) CD/stress 
group with saline prior to stress; (2) CD/stress group with ethyl pyruvate prior to stress; (3) 
CD/stress group with glycyrrhizin prior to stress; (4) ED/stress group with saline prior to 
stress; (5) ED/stress group with ethyl pyruvate prior to stress; and (6) ED/stress group with 
glycyrrhizin prior to stress.  
Statistical Analysis 
All data were evaluated for statistical significance with student’s t-test or one- or two-
way ANOVAs as appropriate using Graph Pad Prism 4.0 (Graph Pad Software, Inc., San 
Diego, CA) and expressed as mean ± SEM.  P-values < 0.05 were considered statistically 
significant.    
Results 
Time Course of Changes in Cytokines, TLR4 and HMGB1 Following Restraint Stress 
 Previous studies have shown an increase in brain cytokines following stress 
(Blandino et al., 2009; Deak et al., 2005; Knapp et al., 2011, Suzuki et al., 1997).  A 1-hr 
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restraint stress significantly increased CCL2, IL1-β and TNFα mRNA (Fig. 4.1).  CCL2 
mRNA expression peaked between 2 and 4 hr (120.7% and 111.2% increase over controls, 
respectively, all p<0.05) and returned to control levels by 8 hr following the stress (Fig. 
4.1A).  IL1-β mRNA was also elevated by the 1-hr restraint stress (Fig. 4.1B).  IL1-β mRNA 
expression peaked at 2 hr (92.1% over controls, p<0.01) after restraint stress.  Although not 
statistically significant, at 4 hr, IL1-β mRNA levels remained high (78.2% of control, 
p>0.05) and had returned to control levels by 8 hr following the stress.  A 1-hr restraint stress 
increased TNFα mRNA expression that peaked at 2 hr (98.5% over controls, p<0.01) (Fig. 
4.1C).  TLR4 mRNA expression was also significantly elevated following a 1-hr restraint 
stress and peaked at 4 hr (68.2% over controls, p<0.05) (Fig. 4.1D).  HMGB1 mRNA 
expression was significantly decreased 24 to 48 hrs. following a 1-hr restraint stress, (40.8% 
and 44.4% below control levels, respectively, p<0.05) (Fig. 4.2).   
Effect of Stress Challenge Following Continuous Ethanol Exposure on Cytokines, TLR4 and 
HMGB1 
 It was established in Chapter III that continuous ethanol exposure for 15 consecutive 
days at 7% ethanol in liquid diet elevated mRNA for cytokines CCL2, IL1-β, and TNFα.  
Previous studies have shown that restraint stress is also capable of elevating cytokines in 
brain (Blandino et al., 2009; Deak et al., 2005; Knapp et al, 2011).  To determine whether 
continuous ethanol exposure sensitizes the neuroimmune system to future challenges, rats 
were exposed to continuous ethanol and challenged with a 1-hr restraint stress 24 hr later.  A 
1-hr restraint stress in CD-treated rats caused a 148% (p<0.05) increase in CCL2 mRNA.  
Continuous ethanol exposure with 24 hr of withdrawal alone caused a 145% (p<0.05) 
increase. Stress challenge following continuous ethanol had an additive effect resulting in a 
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283% (p<0.01) increase in CCL2 mRNA (Fig. 4.3A).  Restraint stress in CD-treated rats 
caused an 88% (p<0.05) increase in IL1-β mRNA.  Continuous ethanol exposure alone 
caused a 97% (p<0.05) increase in IL1-β mRNA. Stress following continuous ethanol 
exposure had an additive effect and elevated IL1-β expression 186% (p<0.01) (Fig. 4.3B).  
Stress in CD-treated rats caused a 98% (p<0.05) increase in TNFα mRNA expression over 
controls.  Ethanol exposure with 24 hr of withdrawal caused a 125% (p<0.05) increase in 
message.  A stress challenge following continuous ethanol exposure caused a 126% increase 
in TNFα mRNA (Fig. 4.3C).  Finally, stress in CD-treated rats caused a 78% (p<0.05) 
increase in mRNA for TLR4s.  Ethanol exposure with 24 hr of withdrawal alone caused a 
76% (p<0.05) increase in message.  Stress after ethanol exposure caused an 88% (p<0.05) 
increase in TLR4 mRNA (Fig. 4.3D).  
 To follow up on the observation of elevated HMGB1 mRNA following continuous 
ethanol exposure (Chapter III), changes in HMGB1 message following a stress challenge 
were determined in continuous-ethanol-exposed rats.  A stress challenge in CD-treated rats 
did not increase HMGB1 mRNA (p>0.05).  However, ethanol alone with 24 hr of withdrawal 
caused a 108 % (p<0.01) increase in HMGB1 message.  A stress challenge after continuous 
ethanol exposure did not have an additive effect and resulted in a 98% (p<0.05) increase in 
HMGB1 mRNA over controls (Fig. 4.4).   
Blockade of HMGB1 Action with Ethyl Pyruvate and Glycyrrhizin  
 HMGB1 has been shown to activate TLR4s to induce proinflammatory cytokines 
(Park et al., 2004).  Additionally, continuous ethanol exposure has been shown to increase 
HMGB1 mRNA expression (Chapter III; Crews et al., submitted).  To further explore the 
idea that HMGB1 is responsible for the neuroimmune system sensitization following chronic 
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ethanol exposure, HMBG1 was blocked with ethyl pyruvate or glycyrrhizin i.p. 15 minutes 
prior to a stress challenge after continuous ethanol exposure.  Treatment with ethyl pyruvate 
or glycyrrhizin prior to stress application did not affect CCL2 levels (p>0.05) in CD-treated 
rats.  However, in continuous- ethanol-treated rats, ethyl pyruvate and glycyrrhizin 
significantly reduced CCL2 mRNA expression when applied before the stress (170.2% and 
164.5% reduction in mRNA expression, respectively, p<0.01) compared to continuous-
ethanol-treated rats given stress and treated with saline (Fig. 4.5).  Treatment with ethyl 
pyruvate or glycyrrhizin prior to stress application had no effect on IL1-β levels (p>0.05) in 
CD-treated rats.  Treatment with ethyl pyruvate or glycyrrhizin prior to stress in continuous-
ethanol-treated rats reduced IL1-β mRNA expression (164% and 177% reduction in mRNA 
expression, respectively, p<0.01) compared to continuous-ethanol-treated rats given stress 
and treated with saline (Fig. 4.5B).  Treatment with ethyl pyruvate or glycyrrhizin prior to 
stress had no effect on TNFα levels (p>0.05) in CD-treated rats.  However, a nonsignificant 
36.7% decrease in TNFα expression was observed in the CD rats treated with glycyrrhizin 
prior to stress.  Treatment with ethyl pyruvate or glycyrrhizin prior to stress in continuous-
ethanol-treated rats reduced TNFα mRNA (ethyl pyruvate, 49% reduction, p<0.05; 
glycyrrhizin, 82% reduction, p<0.01) compared to continuous-ethanol-treated rats given 
stress and treated with saline (Fig. 4.5C).  Treatment with ethyl pyruvate or glycyrrhizin prior 
to stress in CD-treated rats or continuous-ethanol-treated rats did not significantly alter TLR4 
mRNA expression (all p>0.05) (Fig. 4.5D).  Neither ethyl pyruvate nor glycyrrhizin affected 
mRNA levels for HMGB1 in CD-treated animals or continuous-ethanol-treated animals (all 
p>0.05) (Fig. 4.6). 
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Discussion 
 Clinical investigations have demonstrated that stress in abstinent alcoholics can 
induce craving—a circumstance that can increase the probability of relapse (see Breese et al., 
2011; Sinha, 2001).  In accord with this observation, basic research has demonstrated that 
stress-induced anxiety is facilitated following chronic ethanol exposure. Corticotropin 
releasing factor (CRF) is widely known to play a critical role in stress, but the greater 
neurochemical milieu in which CRF acts is poorly understood.  Stress has been shown to 
increase cytokines in brain (Blandino et al., 2009; Deak et al., 2005), and cytokines can 
substitute for stress to facilitate ethanol withdrawal anxiety (Breese et al., 2008).  The present 
effort tested the hypothesis that the increase in cytokines by stress after continuous ethanol 
exposure would be facilitated by the release of the endogenous TLR4 agonist HMGB1.  
 To establish the best time for sacrificing animals after stress, the time course of 
change in cytokines following a 1-hr restraint stress was defined.  The stress caused 
significant increases in CCl2, IL1β, and TNFα mRNAs that peaked in 2 to 4 hr—a finding in 
agreement with previous demonstrations of stress-induced increases in cytokines (Blandino 
et al., 2009; Deak et al., 2005; Minami et al., 1991; Nguyen et al., 1998; Shizuya et al., 1997; 
Suzuki et al., 1997).  Stress represents a unique challenge to the neuroimmune system in that 
it activates cytokine production in a sterile environment; stress in and of itself is not a ligand 
for known receptors of the neuroimmune system (Andersson and Tracey, 2011). To further 
elucidate the mechanism by which stress activates the neuroimmune system, the effects of 
acute stress on the levels of TLR4 and HMGB1 mRNAs were determined.  TLR4 mRNA 
was increased by 68% over controls 4 hr after application of stress.  TLR4 mRNA returned to 
control levels by 8 hr and remained there until at least 48 hr after stress.  HMGB1 mRNA did 
not show an immediate response to acute stress but dropped to 40% of control by 24 hr and 
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remained at this level through the last post-stress time point assessed at 48 hr.  The level of 
HMGB1 was reduced below control levels 7 days after removal from chronic ethanol, a 
pattern of results similar to that observed with stress (Chapter III).  This finding suggests that 
some adaptation in this ligand occurs after a challenge to the immune system.  Such a 
detailed assessment of the effects of acute stress on the time course of changes in TLR4 and 
HMGB1 mRNAs has not previously been reported. The mechanism of the protracted change 
in HMGB1 warrants further investigation.   
 To explore whether stress would enhance the effects of chronic ethanol on cytokine 
levels (Chapter III), restraint stress was applied for 60 min 24 hr after the continuous ethanol 
protocol.  Two recent reports (Barnum et al., 2008; Girotti et al., 2011) provide evidence that 
the neuroimmune system can have a differential response depending on prior experience—in 
this case, chronic ethanol prior to the stress. Additionally, Qin et al. (2007) have shown 
elevated levels of TNFα protein 10 months after a single systemic administration of LPS.  In 
the current investigation, mRNAs for CCL2 and IL1-β were both elevated by stress above the 
level observed 24 hr after the continuous ethanol exposure.  This finding is consistent with a 
behavioral impact of stress-induced cytokines after chronic ethanol exposure (Breese et al., 
2004). Surprisingly, stress did not increase TNFα mRNA beyond the increase seen with 
chronic ethanol exposure alone. This difference from the other cytokines suggests that TNFα 
may be controlled by a different mechanism.  
Combining stress with the chronic ethanol did not elevate the mRNA for TLR4 over 
that observed with stress or chronic ethanol alone. Likewise, the increase in HMGB1 by the 
continuous ethanol protocol was not further increased by stress.  Perhaps the failure to 
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observe stress-associated additive changes in HMGB1 is related to the lack of a stress-
associated increase in HMGB1 in controls.   
The mRNA results for HMGB1 do not support the hypothesis that HMGB1 mediates 
cytokine increases via an interaction of stress and chronic ethanol.  Therefore, an alternative 
explanation, based upon evidence that HMGB1 must be actively released from cells (Kim et 
al., 2006; Park et al., 2004; Yang et al., 2005), was explored.  To evaluate directly whether 
the addition of stress after chronic ethanol induces release of HMGB1, HMGB1 was 
pharmacologically blocked prior to the stress challenge with two different agents.  The first 
agent, ethyl pyruvate, is a cytokine release inhibitory drug (CRID) (Girard, 2007).  Ethyl 
pyruvate has been shown to block the release of HMGB1 from cells without altering its 
expression of mRNA or protein (Ulloa et al., 2002).  The second agent, glycyrrhizin, is an 
effective antagonist of HMGB1 function in vivo (Ohnishi et al., 2011).  Glycyrrhizin inhibits 
HMGB1 by binding it in the extracellular space after release (Girard, 2007; Mollica et al., 
2007).  Both ethyl pyruvate and glycyrrhizin profoundly inhibited the stress-induced 
increases in CCL2 and IL1-β in the rats treated with the continuous ethanol protocol (Fig. 
4.5A and B).  While stress did not further elevate the TNFα mRNA after continuous alcohol, 
HMGB1 antagonists still affected TNFα mRNA level—an effect not observed with the other 
cytokines.  Additionally, neither the TLR4 mRNA level nor the HMGB1 mRNA level was 
affected by the HMGB1 antagonists with or without continuous ethanol exposure although 
HMGB1 was elevated by ethanol exposure alone.  These outcomes are consistent with the 
previous report that ethyl pyruvate does not alter expression of HMGB1 but does prevent its 
release from cells (Ulloa et al., 2002). 
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 Surprisingly, neither glycyrrhizin nor ethyl pyruvate altered the stress-induced 
increase in cytokines in controls although these HMGB1 antagonists reduced mRNA for 
CCL2 and IL1-β to the level observed with chronic ethanol alone—a change equivalent to 
that of stress alone (Fig. 4.5A and B).  These results suggest that HMGB1antagonism 
following continuous ethanol exposure blocks the stress-induced release of cytokines as the 
levels were reduced to the same levels as with continuous ethanol alone.  In the absence of 
prior continuous ethanol exposure stress does not seem to operate by the same mechanism.  
Specifically, HMGB1 antagonism prior to a stress challenge in CD treated animals had no 
effect on cytokine production.  Taken together, these results suggest that acute stress may 
operate under two distinct mechanisms in the two different conditions.  Without prior 
continuous ethanol exposure, acute stress uses one of these mechanisms to evoke cytokines 
in brain.  Given the available explanation in the literature, CRF activation of microglia and 
release of cytokines (Wang et al., 2003) may explain the observed results with regard to 
acute stress.  However, with prior continuous ethanol exposure, the data suggest that stress 
contributes to the release of already elevated HMGB1 levels to further enhance cytokine 
production.  It is likely that CRF is still playing a role but only in so far as setting the release 
of HMGB1 in motion.  The observation that the HMGB1 antagonists prevented the action of 
stress after chronic ethanol exposure is consistent with this view.  Furthermore, CRF 
signaling is recruited following alcohol dependence (Heilig and Koob, 2007), which may 
help explain the apparent dual role of stress following continuous ethanol exposure in the 
current study.  This potential certainly warrants further investigation as the exact mechanism 
by which stress activates the neuroimmune system is heretofore unknown.    
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 Taken together, these data provide evidence that HMGB1 contributes to the increased 
sensitivity of the neuroimmune system to stress following continuous ethanol exposure but 
not to stress-induced increases in cytokines in controls.  Such HMGB1-mediated activation 
of the neuroimmune system following continuous ethanol exposure is consistent with the 
proposal that non-infection-based central disorders may be mediated in part by HMGB1 
(Anderson and Tracey, 2011).  In this regard, HMGB1 has been shown to be elevated in 
many disorders including sepsis (Wang et al., 1999), arthritis and cancer (Lotze and Tracey 
2005), multiple sclerosis (Andersson et al., 2008), epilepsy (Moroso et al., 2010) and 
alcoholism (Crews et al., submitted).  Therapeutic options under development based on these 
findings (Yang et al., 2002; Mollica et al., 2007) may prove to be effective in preventing the 
consequences of neuroimmune diseases as well as relapse in alcoholics. 
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Figure 4.1: Time course of changes in mRNAs for CCL2, IL1-β, and TNFα and for TLR4s 
following 1-hr restraint stress. Stress increased mRNAs for cytokines CCL2, IL1-β, and 
TNFα and for TLR4s.  A) CCL2 mRNA was elevated by stress (F(5,32)=3.82, p=0.008) and 
peaked at 2 to 4 hr after the stress.  B) IL1-β mRNA was elevated by stress (F(5,33)=5.04, 
p=0.015)  and peaked 2 hr after the stress.  C) TNFα mRNA was elevated by stress 
(F(5,38)=8.5, p<0.0001) and peaked 2 hr after the stress. D) TLR4 mRNA was elevated by 
stress (F(5,39)=6.26, p=0.0002) and peaked at 4 hr after the stress.  *p<0.05 compared to 
controls, **p<0.01 compared to controls. 
 
 
 
 
 
 
 
 
 48 
 
 
HMGB1 mRNA
No
 St
res
s
2 h
rs
4 h
rs
8 h
rs
24
 hr
s
48
 hr
s
0
50
100
150
200 No Stress
Stress
* *
%
 o
f C
on
tr
ol
 
Figure 4.2: Time course of changes in mRNA for HMGB1 following 1-hr restraint stress. 
Stress causes a decrease in HMGB1 by 24 hr, an effect that persisted through at least 48 hr 
(F(5,36)=5.35,  p=0.0061).  *p<0.05 compared to controls 
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Figure 4.3: Effects of continuous ethanol and stress on mRNA for cytokines CCL2, IL1-β, 
TNFα and for TLR4s.  Both stress and continuous ethanol increased CCL2, IL1-β, TNFα, 
and for TLR4 mRNA.  A) Both stress (F(1,28)=16.0, p=0.0004) and ethanol (F(1,28)=15.3, 
p=0.0005) increased CCL2. No interaction of stress and ethanol was observed (p>0.05).  B) 
Both stress (F(1,31)=10.9, p=0.0024) and ethanol exposure (F(1,31)=13.4, p=0.0009) 
increased IL1-β.  No interaction of stress and ethanol was observed (p>0.05).  C) Both stress 
(F(1,44)=4.9, p=0.031) and ethanol (F(1,44)=11.7, p=0.031) increased TNFα. The interaction 
of stress and ethanol was significant (F(1,44)=4.8, p=0.033). D) Both stress (F(1,41)=4.4, 
p=0.04) and ethanol  (F(1,41)=4.0, p=0.05) increased TLR4.  No interaction of stress and 
ethanol was observed (p>0.05).  *p<0.05 compared to controls, **p<0.01 compared to 
controls.  
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Figure 4.4:  Effects of continuous ethanol and stress on mRNA for HMGB1.  HMGB1 was 
elevated by continuous ethanol (F(1,36)=24.65, p<0.0001) but not by stress (p>0.05).  No 
interaction between ethanol exposure and stress was observed (p>0.05). **p<0.01 compared 
to controls.  
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Figure 4.5: Effect of HMGB1 blockade with ethyl pyruvate and glycyrrhizin on mRNAs for 
CCL2, IL1-β, and TNFα and for TLR4s following a stress challenge after continuous ethanol 
exposure.  A) Neither ethyl pyruvate nor glycyrrhizin blocked the increase of CCL2 mRNA 
caused by stress in CD-treated rats (p>0.05), but both caused a significant decrease in the 
CCL2 mRNA caused by stress in ED-treated rats (F(2,24)=8.22, p=0.0019).  B) IL1-β 
mRNA was not reduced by ethyl pyruvate or glycyrrhizin after stress in CD-treated animals, 
but both caused a decrease in mRNA caused by stress in ED-treated rats (F(2,20)=44.48, 
p<0.001).  C) TNFα mRNA was not reduced by ethyl pyruvate or glycyrrhizin after stress in 
CD- treated animals, but both caused a significant decrease in mRNA caused by stress in ED-
treated rats (F(2,24)=8.22, p=0.0019).  D) Neither ethyl pyruvate nor glycyrrhizin affected 
mRNA for TLR4 in either CD- or ED-treated animals. *p<0.05 compared to controls, 
**p<0.01 compared to controls.  
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Figure 4.6: Effect of HMGB1 blockade with ethyl pyruvate and glycyrrhizin on mRNA for 
HMGB1 following a stress challenge 24 hr after withdrawal from continuous ethanol 
exposure.  Treatment with ethyl pyruvate or glycyrrhizin prior to stress in CD-treated rats did 
not affect HMGB1 mRNA levels (p>0.05).  Neither ethyl pyruvate nor glycyrrhizin blocked 
the effects of stress on HMGB1 mRNA levels after ED exposure in rats (p>0.05).   
  
 
CHAPTER V: 
GENERAL DISCUSSION 
 
Clinically, stress has been shown to play a role in craving and risk of relapse (Breese 
et al., 2005b; 2010; Sinha et al., 2000; Miller et al., 2009; Sinha et al., 2011).  In abstinent 
alcoholics, stress increases fMRI signals in brain that are accompanied by craving—changes 
not apparent in social drinkers (Breese et al., 2011 for review).  Consistent with this finding, 
chronic intermittent alcohol exposure facilitated the anxiety response to restraint stress in rats 
(Breese et al., 2005b).  Stress powerfully activates the neuroimmune system (Blandino et al., 
2009; Deak et al., 2005; Girotti et al., 2011; Hueston et al., 2011; Minami et al., 1991; 
Nguyen et al., 1998, 2000; Shizuya et al., 1997; Suzuki et al., 1997; Knapp et al., 2011). 
Cytokines, which are increased in brain by various types of stressors (Blandino et al., 2009; 
Deak et al., 2005; Girotti et al., 2011; Hueston et al., 2011; Minami et al., 1991; Nguyen et 
al., 1998, 2000; Shizuya et al., 1997; Suzuki et al., 1997; Knapp et al., 2011), are potential 
mediators of the negative affect associated with the interaction of chronic ethanol and stress.   
Like stress, chronic alcohol administration increases cytokines in brain (Alfonso-
Loeches et al., 2010; Blanco et al., 2005; Crews et al., submitted; Fernandez-LIzarbe et al., 
2008). While infection is known to activate cytokines as part of the immune response, both 
stress and ethanol increase cytokines in a “sterile” environment in the absence of infection.  
The present body of work for this dissertation explored the possible basis of how alcohol and 
stress could increase cytokines in brain.  
Previous literature provides clear evidence that ethanol’s influence on cytokines 
involves the TLR4 (Alfonso-Loeches et al., 2010; Blanco et al., 2005; Fernandez-Lizarbe et 
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al., 2009). The Guerri laboratory proposed that ethanol activates cytokines by influencing a 
lipid raft to activate TLR4 (Fernandez-Lizarbe et al., 2008).  However, while agents such as 
LPS are direct agonists at the TLR4 (Triantafilou et al., 2002), ethanol has not been shown to 
date to be a direct agonist of any known receptor.  A non-agonist (ethanol) should not be 
capable of  stimulating TLR4s directly; however, several studies using TLR4 knockout mice 
reveal a lack of sensitivity to ethanol (Alfonso-Loeches et al., 2010; Fernandez-Lizabre et al., 
2009; Pascual et al., 2011; Uesugi et al., 2001, Wu et al., 2012).  Because ethanol is unlikely 
to have a direct agonist action on TLR4, the acute and chronic actions of LPS and ethanol 
were compared to explore other possible modes by which ethanol could activate TLR4 and 
the neuroimmune system.  
A comparison of the effects of LPS and ethanol on brain cytokines provided 
considerable insight into the in vivo action of ethanol.  This effort (Chapter III) clearly 
differentiated the effects of LPS from those of ethanol on brain cytokines.  A moderate acute 
dose of ethanol did not affect brain cytokine mRNA whereas an acute dose of LPS did.  This 
finding is important in demonstrating fundamental differences in the mechanism by which 
LPS, a direct TLR4 agonist, and ethanol activate TLR4s to increase brain cytokines, the work 
of Fernandez-Lizabre (2008) notwithstanding.  The comparison of chronic LPS exposure to 
continuous ethanol further highlights the difference in the mechanisms by which ethanol and 
LPS act on TLR4s.  Continuous ethanol caused considerable elevation in brain cytokines 
whereas chronic LPS caused endotoxin tolerance.  This marked difference between ethanol 
and LPS in neuroimmune system effects is consistent with a corresponding difference in 
potential mechanisms by which each affects the TLR4. 
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Possible mechanisms of the differential activation of the neuroimmune system by 
ethanol and LPS were explored.  An endogenous TLR4 agonist, HMGB1, was discovered to 
be significantly elevated following 15 days of continuous ethanol exposure but not following 
chronic LPS exposure.  This finding is consistent with the possibility that ethanol could 
elevate brain cytokines via HMGB1 when LPS was no longer able to do so.  This finding is 
of considerable importance both to understanding targets for intervening in the progression of 
alcoholism and to further defining the mechanism by which ethanol is capable of influencing 
TLR4 signaling.  Figure 5.1A depicts a model of the increase in HMGB1 following 
continuous ethanol exposure.  In this model, HMGB1 is elevated by continuous ethanol and 
further elevated by withdrawal to provide a potent potential for enhanced cytokine expression 
in the instance of a further challenge. 
Building on the findings from Chapter III, Chapter IV focused on whether HMGB1 
could be involved in the facilitation of the stress-induced cytokine response after continuous 
ethanol exposure.  Clinically, stress has been shown to play a role in craving and risk of 
relapse (Breese et al., 2005b; 2010; Sinha et al., 2000; Miller et al., 2009; Sinha et al., 2011).  
Additionally, stress is known to be a powerful activator of the neuroimmune system 
(Blandino et al., 2009; Deak et al., 2005; Girotti et al., 2011; Hueston et al., 2011; Minami et 
al., 1991; Nguyen et al., 1998, 2000; Shizuya et al., 1997; Suzuki et al., 1997; Knapp et al., 
2011).  As predicted, the addition of a stress challenge following continuous ethanol 
exposure caused an additive increase in cytokines CCL2 and IL1-β.  No further increase in 
TLR4s or HMGB1 in response to stress following continuous ethanol exposure was 
observed.  Stress in the absence of prior ethanol exposure had no effect on HMGB1 mRNA 
levels until 24 hr, at which time levels were reduced to less than half those of controls.  The 
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latter finding potentially reflects adaptive regulation of HMGB1.  To further define the role 
of HMGB1 following continuous ethanol exposure, HMGB1 was pharmacologically blocked 
just prior to the stress challenge.  Blocking HMGB1 signaling had a profound effect on the 
stress-induced increase in CCL2 and IL1-β mRNA and also reduced the level of TNFα, 
which was not further elevated by stress following continuous ethanol exposure.  Based on 
these results, a model of the influence of stress on the already primed neuroimmune system 
following continuous ethanol exposure is depicted in Figure 5.1B.  Since blockade of 
HMGB1 did not abrogate the increase in cytokines observed in stress-only controls, it is 
hypothesized that (1) continuous ethanol elevates HMGB1; and (2) the addition of stress to 
an already primed system is responsible for HMGB1 release from cells in order to activate 
the cell surface TLR4s.  Thus, stress following continuous ethanol exposure further 
stimulates the neuroimmune system to cause a more pronounced increase in brain cytokines.    
Future Work 
 The time course of changes in brain cytokines following withdrawal from continuous 
ethanol exposure in Chapter III indicated that HMGB1 mRNA levels were elevated prior to 
ethanol removal.  However, because HMGB1 must be released from the cell in order to 
activate cell surface receptors like TLR4 (Kim et al., 2006), it is unclear whether this early 
rise in HMGB1 contributes to the increase in brain cytokines, which are not elevated until 24 
hr following withdrawal from continuous ethanol.  Future studies should define the role of 
HMGB1 in stimulating brain cytokines following continuous ethanol exposure. 
 Data from Chapter IV indicate that stress in the absence of previous ethanol exposure 
had no early effects on HMGB1 and served to reduce levels at time points beyond 24 hr.  
Stress under various conditions has been shown to cause increases in brain cytokines 
 57 
 
(Minami et al., 1991; Nguyen et al., 1998).  However, neither the literature nor the current 
data provide a good mechanism for stress activation of the neuroimmune system.  Sugama et 
al. (2009) describe data showing that stress can differentially activate microglia when 
compared to LPS activation in the same brain area.  This research implicates a specialized 
role for neurons to contribute directly to stress-induced increased in brain cytokines.  
Additionally, Wang et al. (2002; 2003) demonstrated functional expression of CRF receptors 
and induction of TNFα release following application of CRF in cultured microglia cells.  The 
exact mechanism by which stress induces brain cytokines warrants further investigation. 
 Previous studies indicate that ethanol sensitivity might vary by brain area (Huang et 
al., 2010; Overstreet et al., 2006).  The present effort focused on changes in the cortex, an 
area previously shown to have clinical relevance to human alcoholics (He and Crews, 2008; 
Crews et al., submitted).  It remains to be determined whether areas of the brain associated 
with withdrawal-induced anxiety (Huang et al., 2010) or stress (Deak et al., 2005; Suguma et 
al., 2009) are differentially affected by continuous ethanol.   
 Antagonism of HMGB1 blocked the stress-induced increase in cytokines following 
continuous ethanol exposure.  HMGB1 can signal though several receptors including TLR2 
and receptor for advanced glycation end product (RAGE) (Green et al., 2009; Park et al., 
2006; Rovere-Querini et al., 2004 Yu et al., 2006) and can act as a universal sentinel for 
nucleic acid-mediated immune response (e.g., TLRs 3, 7, 9) Yanai et al., 2009).  Blocking 
HMGB1 with ethyl pyruvate or glycyrrhizin prevents its action on all of these receptors.  
However, blocking HMGB1 directly provides little evidence as to the concomitant 
contribution of other neuroimmune receptors to cytokine induction after continues ethanol 
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exposure.  Therefore, the relative contribution of TLR4s could be determined by directly 
antagonizing the TLR4 following continuous ethanol exposure.  
  
  
Figur
Figur
contin
and m
can b
the sy
es 
e 5.1: Mode
uous ethan
ay contribu
e used to fur
stem follow
ls depicting
ol exposure.
te to the ele
ther stimula
ing chronic
 the influenc
 A) HMGB
vated levels
te the neuro
 ethanol exp
59 
e of HMGB
1 is elevated
 of cytokine
immune sys
osure.   
1 on neuroi
 following c
s.  B) The el
tem when a
mmune sign
ontinuous e
evated leve
 challenge i
aling follow
thanol expo
ls of HMGB
s presented t
 
ing 
sure 
1 
o 
 60 
 
REFERENCES 
Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. (2000)  HMGB1 as a mediator of 
acute lung inflammation.  J Immunol. 165(6):2950-4. 
Akira S, Takeda K. (2004) Toll-like receptor signaling. Nat Rev Immunol.  4(7):499-511. 
Alfonso-Loeches S, Pascual-Lucas M, Blanco AM, Sanchez-Vera I, Guerri C. (2010) Pivotal 
role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. J Neurosci. 
30(24):8285-95. 
Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, Wallström 
E, Lobell A, Brundin L, Lassmann H, Harris RA. (2008) Pivotal advance: HMGB1 
expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol. 
84(5):1248-55.  
Andersson U, Tracey KJ. (2011) HMGB1 is a therapeutic target for sterile inflammation and 
infection. Annu Rev Immunol. 29:139-62. 
Baeuerle PA, Henkel T. (1994) Function and activation of NF-kappa B in the immune 
system. Annu Rev Immunol. 12:141-79. 
Barnum CJ, Blandino P Jr, Deak T. (2008) Social status modulates basal IL-1 concentrations 
in the hypothalamus of pair-housed rats and influences certain features of stress reactivity. 
Brain Behav Immun. 22(4):517-27. 
Blanco AM, Vallés SL, Pascual M, Guerri C. (2005) Involvement of TLR4/type I IL-1 
receptor signaling in the induction of inflammatory mediators and cell death induced by 
ethanol in cultured astrocytes. J Immunol. 175(10):6893-9. 
Blandino, P, CJ Barnum, LG Solomon, Y Larish, BS Lankow and T Deak. 2009. Gene 
expression changes in the hypothalamus provide evidence for regionally-selective changes in 
IL-1 and microglial markers after acute stress. Brain Behav Immun.  23:958–968. 
Breese GR, Chu K, Dayas CV, Funk D, Knapp DJ, Koob GF, Lê DA, O'Dell LE, Overstreet 
DH, Roberts AJ, Sinha R, Valdez GR, Weiss F. (2005b) Stress enhancement of craving 
during sobriety: a risk for relapse. Alcohol Clin Exp Res. 29(2):185-95. 
 61 
 
Breese GR, Knapp DJ, Overstreet DH, Navarro M, Wills TA, Angel RA. (2008) Repeated 
lipopolysaccharide (LPS) or cytokine treatments sensitize ethanol withdrawal-induced 
anxiety-like behavior. Neuropsychopharmacology. 33(4):867-76. 
Breese GR, Knapp DJ, Overstreet DH. (2004) Stress-induced anxiety-like behavior during 
abstinence from previous chronic ethanol exposure. Alcohol Clin Exp Res. 28:191A. 
Breese GR, Overstreet DH, Knapp DJ (2005a) Conceptual framework for the etiology of 
alcoholism: a "kindling"/stress hypothesis. Psychopharmacology (Berl). 178:367-380. 
Breese GR, Overstreet DH, Knapp DJ, Navarro M. (2005c)  Prior multiple ethanol 
withdrawals enhance stress-induced anxiety-like behavior: inhibition by CRF1- and 
benzodiazepine-receptor antagonists and a 5-HT1a-receptor agonist. 
Neuropsychopharmacology. 30(9):1662-9. 
Breese GR, Sinha R, Heilig M (2011) Chronic alcohol neuroadaptation and stress contribute 
to susceptibility for alcohol craving and relapse. Pharmacology & Therapeutics. 129:149-
171. 
Buck HM, Hueston CM, Bishop C, Deak T. (2011) Enhancement of the hypothalamic-
pituitary-adrenal axis but not cytokine responses to stress challenges imposed during 
withdrawal from acute alcohol exposure in Sprague-Dawley rats. Psychopharmacology 
218(1):203-15. 
Carson, E J and SB Pruett. 1996. Development and characterization of a binge drinking 
model in mice for evaluation of the immunological effects of ethanol. Alcohol Clin Exp Res. 
20:1: 132-138. 
Chen R, Zhou H, Beltran J, Malellari L, Chang S. (2005) Differential expression of cytokines 
in the brain and serum during endotoxin tolerance. Journal of Neuroimmunology.163:53–72. 
Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, 
Wheeler M, Zou J. (2006) Cytokines and alcohol. Alcohol Clin Exp Res. 30(4):720-30. 
Crews, F, Qin L, Sheedy D, Vetreno, Zou J. (submitted). Increased DANGER Signaling 
through HMGB1 and TLR Receptors in Alcohol. Biol Psychiatry. 
Dai Q, Zhang J, Pruett SB. (2005) Ethanol alters cellular activation and CD14 partitioning in 
lipid rafts. Biochem Biophys Res Commun. 332(1):37-42. 
 62 
 
Deak T, Bellamy C, D'Agostino LG. (2003) Exposure to forced swim stress does not alter 
central production of IL-1. Brain Res. 972(1-2):53-63. 
Deak T, Bordner KA, McElderry NK, Barnum CJ, Blandino P Jr, Deak MM, Tammariello 
SP. (2005) Stress-induced increases in hypothalamic IL-1: a systematic analysis of multiple 
stressor paradigms. Brain Res Bull. 64(6):541-56. 
DSM IV. American Psychiatric Association. (1994). Diagnostic and statistical manual of 
mental disorders (4th ed.). Washington, DC. 
Ellwood KB, Yen YM, Johnson RC, Carey M. (2000) Mechanism for specificity by HMGB1 
in enhanceosome assembly. Mol Cell Biol. 20:4359–4370. 
Erridge C, Bennett-Guerrero E, Poxton IR. (2002) Structure and function of 
lipopolysaccharides. Microbes Infect. 4(8):837-51. 
Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, Sparatore B, Moroni F, Chiarugi 
A. (2007) High mobility group box 1 protein is released by neural cells upon different 
stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem. 
103(2):590-603.  
Fernandez-Lizarbe S, Pascual M, Gascon MS, Blanco A, Guerri C. (2008) Lipid rafts 
regulate ethanol-induced activation of TLR4 signaling in murine macrophages. Mol 
Immunol. 45(7):2007-16. 
Fernandez-Lizarbe S, Pascual M, Guerri C. (2009) Critical role of TLR4 response in the 
activation of microglia induced by ethanol. J Immunol. 183(7):4733-44.  
Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, 
Golenbock DT. (2003) LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll 
adapters TRAM and TRIF. J Exp Med. 198(7):1043-55.  
Frye GD, McCown TJ, Breese GR. (1983) Characterization of susceptibility to audiogenic 
seizures in ethanol-dependent rats after microinjection of gamma-aminobutyric acid (GABA) 
agonists into the inferior colliculus, substantia nigra or medial septum. J Pharmacol Exp 
Ther. 227(3):663-70. 
 63 
 
Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A. (2002) 
The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated 
secretory pathway. EMBO Rep. 3(10):995-1001. 
Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. (2010) 
Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. 
Biochim Biophys Acta. 1805(1):53-71    
Gilman JM, Hommer DW. (2008) Modulation of brain response to emotional images by 
alcohol cues in alcohol-dependent patients. Addict Biol. (3-4):423-34. 
Girard JP. A direct inhibitor of HMGB1 cytokine. (2007) Chem Biol. 14(4):345-7. 
Girotti M, Donegan JJ, Morilak DA. (2011) Chronic intermittent cold stress sensitizes neuro-
immune reactivity in the rat brain. Psychoneuroendocrinology. 36(8):1164-74 
Glezer I, Simard AR, Rivest S. (2007) Neuroprotective role of the innate immune system by 
microglia. Neuroscience. 147(4):867-83 
Godbout JP, Chen J, Abraham J, Richwine AF, Berg BM, Kelley KW, Johnson RW. (2005) 
Exaggerated neuroinflammation and sickness behavior in aged mice following activation of 
the peripheral innate immune system. FASEB J.  19(10):1329-31 
Goodwin, GH, C Sanders and EW Johns (1973) A new group of chromatin-associated 
proteins with a high content of acidic and basic amino acids. Eur J Biochem, 38:14–19 
Green DR, Ferguson T, Zitvogel L, Kroemer G. (2009) Immunogenic and tolerogenic cell 
death. Nat Rev Immunol. 9(5):353-63.  
Hasin DS, Stinson FS, Ogburn E, Grant BF. (2007)  Prevalence, correlates, disability, and 
comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the 
National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 
64(7):830-42. 
He J, and Crews FT. (2008) Increased MCP-1 and microglia in various regions of the human 
alcoholic brain. Exp. Neurol. 210(2):349-58. 
 64 
 
Heilig M, Koob GF. (2007) A key role for corticotropin-releasing factor in alcohol 
dependence. Trends Neurosci. 30(8):399-406. 
Hueston, CM, C J Barnum, JA Eberle, FJ Ferraioli, HM Buck, T Deak. (2011) Stress-
dependent changes in neuroinflammatory markers observed after common laboratory 
stressors are not seen following acute social defeat of the Sprague Dawley rat. Physiol 
Behav. 104(2- 3):187-198. 
Janssens S, Beyaert R. (2002) A universal role for MyD88 in TLR/IL-1R-mediated signaling. 
Trends Biochem Sci. 27(9):474-82. 
Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW, Lee MH, Han PL, Park JS, Lee JK. 
(2006) HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed 
neuroinflammation in the postischemic brain. J Neurosci. 26(24):6413-21. 
Knapp DJ, Crews FT (1999) Induction of cyclooxygenase-2 in brain during acute and 
chronic ethanol treatment and ethanol withdrawal. Alcohol Clin Exp Res. 23:633-643. 
Knapp DJ, Duncan GE, Crews FT, Breese GR.  (1998) Induction of Fos-like proteins and 
ultrasonic vocalizations during ethanol withdrawal: further evidence for withdrawal-induced 
anxiety. Alcohol Clin Exp Res. 22(2):481-93. 
Knapp DJ, Overstreet DH, Angel RA, Navarro M, Breese GR. (2007) The amygdala 
regulates the antianxiety sensitization effect of flumazenil during repeated chronic ethanol or 
repeated stress. Alcohol Clin Exp Res. 31(11):1872-82.  
Knapp DJ, Whitman BA, Wills TA, Angel RA, Overstreet DH, Criswell HE, Ming Z, Breese 
GR. (2011) Cytokine involvement in stress may depend on corticotrophin releasing factor to 
sensitize ethanol withdrawal anxiety. Brain Behav Immun. 25 Suppl 1:S146-54. 
Lin Q, Yang XP, Fang D, Ren X, Zhou H, Fang J, Liu X, Zhou S, Wen F, Yao X, Wang JM, 
Su SB. (2011) High-mobility group box-1 mediates toll-like receptor 4-dependent 
angiogenesis. Arterioscler Thromb Vasc Biol. 31(5):1024-32.  
Ling Z, Zhu Y, Tong C, Snyder JA, Lipton JW, Carvey PM. (2006) Progressive dopamine 
neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to 
LPS prenatally. Exp Neurol. 199(2):499-512. 
 65 
 
Liu J, Lewohl JM, Harris RA, Iyer VR, Dodd PR, Randall PK, Mayfield RD. (2006) Patterns 
of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. 
Neuropsychopharmacology. 31(7):1574-82.  
Lotze MT, Tracey KJ. (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon 
in the immune arsenal. Nat Rev Immunol. 5(4):331-42. 
Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, Rossetti C, Molteni M, 
Casalgrandi M, Manfredi AA, Bianchi ME, Vezzani A. (2010) Toll-like receptor 4 and high-
mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat 
Med. 16(4):413-9. 
McClain CJ, and Cohen DA. (1989) Increased tumor necrosis factor production by 
monocytes in alcoholic hepatitis. Hepatology. 9(3):349-51. 
McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. (1999) Cytokines in alcoholic liver 
disease. Semin Liver Dis. 19(2):205-19. 
McCown TJ, Breese GR. (1990) Multiple withdrawals from chronic ethanol "kindles" 
inferior collicular seizure activity: evidence for kindling of seizures associated with 
alcoholism. 34(5):777- Alcohol Clin Exp Res. 14(3):394-9. 
Miller AH, Maletic V, Raison CL. (2009) Inflammation and its discontents: the role of 
cytokines in the pathophysiology of major depression. Biol Psychiatry. 65(9):732-41.  
Minami M, Kuraishi Y, Yamaguchi T, Nakai S, Hirai Y, Satoh M. (1991) Immobilization 
stress induces interleukin-1 beta mRNA in the rat hypothalamus. Neurosci Lett. 123(2):254-
6. 
Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, Agresti A, 
Trisciuoglio L, Musco G, Bianchi ME. (2007) Glycyrrhizin binds to high-mobility group box 
1 protein and inhibits its cytokine activities. Chem Biol.14(4):431-41. 
Müller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M, Bianchi ME. 
(2001) New EMBO members' review: the double life of HMGB1 chromatin protein: 
architectural factor and extracellular signal. EMBO J. 20(16):4337-40. 
 66 
 
Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR, Maier SF. (1998) 
Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci. 
18(6):2239-46. 
Nguyen KT, Deak T, Will MJ, Hansen MK, Hunsaker BN, Fleshner M, Watkins LR, Maier 
SF. (2000) Timecourse and corticosterone sensitivity of the brain, pituitary, and serum 
interleukin-1beta protein response to acute stress. Brain Res. 859(2):193-201. 
Nguyen, MD, JP Julien and S Rivest. (2002)  Innate immunity: the missing link in 
neuroprotection andneurodegeneration? Nature reviews. Neuroscience 3(3): 216-227. 
Ohnishi M, Katsuki H, Fukutomi C, Takahashi M, Motomura M, Fukunaga M, Matsuoka Y, 
Isohama Y, Izumi Y, Kume T, Inoue A, Akaike A. (2011) HMGB1 inhibitor glycyrrhizin 
attenuates intracerebral hemorrhage-induced injury in rats. Neuropharmacology. 61(5-
6):975-80. 
Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. (2009) Toll-like 
receptors in neurodegeneration. Brain Res Rev. 59(2):278-92. 
Okvist A, Johansson S, Kuzmin A, Bazov I, Merino-Martinez R, Ponomarev I, Mayfield RD, 
Harris RA, Sheedy D, Garrick T, Harper C, Hurd YL, Terenius L, Ekstro¨m TJ, Bakalkin G, 
Yakovleva T (2007) Neuroadaptations in human chronic alcoholics: dysregulation of the NF-
kappaB system. PLoS ONE 2:e930. 
Overstreet DH, Knapp DJ, Breese GR. (2002) Accentuated decrease in social interaction in 
rats subjected to repeated ethanol withdrawals. Alcohol Clin Exp Res. 26(8):1259-68. 
Overstreet DH, Knapp DJ, Angel RA, Navarro M, Breese GR. (2006) Reduction in repeated 
ethanol-withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 
5-HT2C ligands. Psychopharmacology (Berl). 187(1):1-12. 
Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu 
G, Bianchi ME. (2004) Extracellular HMGB1, a signal of tissue damage, induces 
mesoangioblast migration and proliferation. J Cell Biol. 164(3):441-9.  
Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, 
Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E. (2006) High mobility group 
box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 
290(3):C917-24. 
 67 
 
Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E. (2004) 
Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 
protein. J Biol Chem. 279:7370–7377. 
Pascual M, Baliño P, Alfonso-Loeches S, Aragón CM, Guerri C. (2011) Impact of TLR4 on 
behavioral and cognitive dysfunctions associated with alcohol-induced neuroinflammatory 
damage. Brain Behav Immun. 25 Suppl. 1:S80-91.  
Pascual M, Blanco AM, Cauli O, Minarro J, Guerri C (2007) Intermittent ethanol exposure 
induces inflammatory brain damage and causes long-term behavioural alterations in 
adolescent rats. Eur J Neurosci. 25:541-550. 
Plata-Salamán CR, Ilyin SE, Turrin NP, Gayle D, Flynn MC, Bedard T, Merali Z, Anisman 
H. (2000) Neither acute nor chronic exposure to a naturalistic (predator) stressor influences 
the interleukin-1beta system, tumor necrosis factor-alpha, transforming growth factor-beta1, 
and neuropeptide mRNAs in specific brain regions. Brain Res Bull. 51(2):187-93. 
Pruett BS, and Pruett SB. (2006) An explanation for the paradoxical induction and 
suppression of an acute phase response by ethanol. Alcohol. 39(2):105-10.  
Pruett SB, and Fan R. (2009) Ethanol inhibits LPS-induced signaling and modulates cytokine 
production in peritoneal macrophages in vivo in a model for binge drinking. BMC Immunol. 
10:49. 
Qin L, He J, Hanes RN, Pluzarev O, Hong JS, Crews FT. (2008) Increased systemic and 
brain cytokine production and neuroinflammation by endotoxin following ethanol treatment. 
J Neuroinflammation. 18: 5-10. 
Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. (2007) 
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 
55(5):453-62. 
Rauvala H, Rouhiainen A. (2007) RAGE as a receptor of HMGB1 (Amphoterin): roles in 
health and disease. Curr Mol Med. 7(8):725-34. 
Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, 
Dumitriu IE, Müller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA. (2004) 
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 
5(8):825-30 
 68 
 
Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic 
cells triggers inflammation. Nature. 418(6894):191-5. 
Sha Y, Zmijewski J, Xu Z, Abraham E. (2008) HMGB1 develops enhanced proinflammatory 
activity by binding to cytokines. J Immunol. 180(4):2531-7. 
Shizuya K, Komori T, Fujiwara R, Miyahara S, Ohmori M, Nomura J. (1997) The influence 
of restraint stress on the expression of mRNAs for IL-6 and the IL-6 receptor in the 
hypothalamus and midbrain of the rat. Life Sci. 61(10):PL 135-40. 
Sinha R, Fox HC, Hong KI, Hansen J, Tuit K, Kreek MJ. (2011) Effects of adrenal 
sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and 
treatment outcomes. Arch Gen Psychiatry. 68(9):942-52. 
Su X, Wang H, Zhao J, Pan H, Mao L. (2011) Beneficial effects of ethyl pyruvate through 
inhibiting high-mobility group box 1 expression and TLR4/NF-κB pathway after traumatic 
brain injury in the rat. Mediators Inflamm. 2011:807142. 
Sugama S, Takenouchi T, Fujita M, Conti B, Hashimoto M. (2009) Differential microglial 
activation between acute stress and lipopolysaccharide treatment. J Neuroimmunol. 207(1-
2):24-31. 
Suzuki E, Shintani F, Kanba S, Asai M, Nakaki T. (1997) Immobilization stress increases 
mRNA levels of interleukin-1 receptor antagonist in various rat brain regions. Cell Mol 
Neurobiol. 17(5):557-62. 
Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. (2002) Mediators of innate 
immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-
induced cell activation. J Cell Sci.115(Pt 12):2603-11. 
Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. (2001) Toll-like receptor 4 is 
involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology. 
34(1):101-8. 
Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey 
KJ. (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and 
systemic inflammation. Proc Natl Acad Sci U S A. 99(19):12351-6 
 69 
 
Valles SL, Blanco AM, Azorin I, Guasch R, Pascual M, Gomez-Lechon MJ, Renau-Piqueras 
J, Guerri C. (2003) Chronic ethanol consumption enhances interleukin-1-mediated signal 
transduction in rat liver and in cultured hepatocytes. Alcohol Clin Exp Res. 27(12):1979-86. 
Vartanian K, Stenzel-Poore M. (2010) Toll-like receptor tolerance as a mechanism for 
neuroprotection. Transl Stroke Res. 1(4):252-260. 
Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, 
Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, 
Molina PE, Abumrad NN, Sama A, Tracey KJ. (1999) HMG-1 as a late mediator of 
endotoxin lethality in mice. Science. 285(5425):248-51. 
Wang W, Ji P, Dow KE. (2003) CRF induces proliferation and TNFα release in cultured rat 
microglia via MAP-kinase signaling pathways.  J Neurochem.  84:189-195.     
Wang W, Ji P, Riopelle RJ, Dow KE. (2002) Functional expression of CRH receptor 1 in  
WHO (2009) Alcohol and Drugs. Report on the meeting on indicators for monitoring 
alcohol, drugs and other psychoactive substance use, substance-attributable harm and societal 
responses. In: Abuse, D.o.M.H.a.S. (Ed.), WHO Press, Geneva. 
Wills TA, Knapp DJ, Overstreet DH, Breese GR. (2008) Differential dietary ethanol intake 
and blood ethanol levels in adolescent and adult rats: effects on anxiety-like behavior and 
seizure thresholds. Alcohol Clin Exp Res. 32(8):1350-60.  
Wu Y, Lousberg EL, Moldenhauer LM, Hayball JD, Coller JK, Rice KC, Watkins LR, 
Somogyi AA, Hutchinson MR. (2012) Inhibiting the TLR4-MyD88 signalling cascade by 
genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor 
impairment in mice. Br J Pharmacol. 165(5):1319-29.  
Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, Nakasato M, Lu Y, Hangai S, 
Koshiba R, Savitsky D, Ronfani L, Akira S, Bianchi ME, Honda K, Tamura T, Kodama T, 
Taniguchi T. (2009) HMGB proteins function as universal sentinels for nucleic-acid-
mediated innate immune responses. Nature. 462:99-103. 
Yang H, Wang H, Czura CJ, Tracey KJ. (2002) HMGB1 as a cytokine and therapeutic target. 
J Endotoxin Res. 2002;8(6):469-72. 
 70 
 
Yang H, Wang H, Czura CJ, Tracey KJ. (2005) The cytokine activity of HMGB1. J Leukoc 
Biol. 78(1):1-8.  
Yang QW, Lu FL, Zhou Y, Wang L, Zhong Q, Lin S, Xiang J, Li JC, Fang CQ, Wang JZ. 
(2011) HMGB1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like 
receptor 4 signaling. J Cereb Blood Flow 31(2):593-605. 
Yang QW, Wang JZ, Li JC, Zhou Y, Zhong Q, Lu FL, Xiang J. (2010) High-mobility group 
protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab. 30(2):243-
54 
Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H. 
(2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 26(2):174-9. 
Zou J, Crews F. (2010) Induction of innate immune gene expression cascades in brain slice 
cultures by ethanol: key role of NF-κB and proinflammatory cytokines. Alcohol Clin Exp 
Res.  
